{| class="wikitable" style="text-align:center; width:50%;"
!colspan="2" align="center" style="color:white; font-size:125%; background-color:#de2d26"|'''Section editor'''
|-
|style="background-color:#F0F0F0"|[[File:Sanjay_mohan.png|frameless|upright=0.3|center]]
|<big>[[User:Sanjaymohan|Sanjay R. Mohan, MD, MSCI]]<br>Vanderbilt University<br>Nashville, TN</big>
|-
|}
{| class="wikitable" style="float:right; margin-right: 5px;"
|-
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
|}
{{TOC limit|limit=3}}

=Guidelines=

==ELN==
*'''2013:''' Baccarani et al. [http://www.bloodjournal.org/content/122/6/872.long European LeukemiaNet recommendations for the management of chronic myeloid leukemia] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4915804/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23803709 PubMed]

==ESMO==
*'''2017:''' Hochhaus et al. [https://www.esmo.org/Guidelines/Haematological-Malignancies/Chronic-Myeloid-Leukaemia Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up]

==[https://www.nccn.org/ NCCN]==
*[https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf NCCN Guidelines - Chronic Myeloid Leukemia]

=Chronic phase, first-line therapy=

==Bosutinib monotherapy {{#subobject:e8f0a4|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 400 mg/day {{#subobject:eb73f2|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2017.74.7162 Cortes et al. 2017 (BFORE)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Imatinib_monotherapy|Imatinib]]
|style="background-color:#91cf60"|Seems to have superior [[Response_to_treatment#Molecular_response|MMR rate]] at 12 months
|-
|}
====Chemotherapy====
*[[Bosutinib (Bosulif)]] 400 mg PO once per day

'''Continued indefinitely'''

===Variant #2, 500 mg/day {{#subobject:be7de3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979199/ Cortes et al. 2012 (BELA)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Imatinib_monotherapy|Imatinib]]
|style="background-color:#1a9850"|Superior [[Response_to_treatment#Molecular_response|MMR rate]] at 12 months
|-
|}
''Suboptimal response defined as no [[Response_to_treatment#Hematologic_response_.28HR.29|complete hematologic response (CHR)]] by week 8 or [[Response_to_treatment#Cytogenetic_response|complete cytogenetic response (CCyR)]] by week 12.''
====Chemotherapy====
*[[Bosutinib (Bosulif)]] 500 mg PO once per day, take with food
**If no grade 3 or higher drug-related toxicity occurs, dose can be escalated to 600 mg PO once per day if response is suboptimal

'''Continued indefinitely'''

===References===
<!-- 
# Presented in part at the 52nd Annual Meeting of the American Society of Hematology, December 4-7, 2010, Orlando, FL.
# '''Update:''' Jorge E Cortes, Anish Maru, Carmino Antonio Antonio De Souza, François Guilhot, Ladan Duvillie, Christine Powell, Athena Countouriotis, and Carlo Gambacorti-Passerini. Bosutinib Versus Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia – BELA Trial: 24-Month Follow-up. 2011 ASH Annual Meeting Abstract 455. [http://abstracts.hematologylibrary.org/cgi/content/abstract/118/21/455 link to abstract]
# '''Update:''' Carlo Gambacorti-Passerini, Jeffrey Howard Lipton, Goh Yeow Tee, Luis Felipe Casado, Andrey Zaritskey, Philipp D. le Coutre, Ladan Duvillie, Dmitri Pavlov, Athena Maria Countouriotis, Jennifer Byrne. BELA trial update: Bosutinib (BOS) versus imatinib (IM) in patients (pts) with newly diagnosed chronic phase chronic myeloid leukemia (CP CML) after 30 months of follow-up. 2012 ASCO Annual Meeting abstract 6512. [http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=100550 link to abstract] -->
# '''BELA:''' Cortes JE, Kim DW, Kantarjian HM, Brümmendorf TH, Dyagil I, Griskevicius L, Malhotra H, Powell C, Gogat K, Countouriotis AM, Gambacorti-Passerini C. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012 Oct 1;30(28):3486-92. Epub 2012 Sep 4. [http://jco.ascopubs.org/content/30/28/3486.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979199/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22949154 PubMed]
## '''Update:''' Gambacorti-Passerini C, Cortes JE, Lipton JH, Dmoszynska A, Wong RS, Rossiev V, Pavlov D, Gogat Marchant K, Duvillié L, Khattry N, Kantarjian HM, Brümmendorf TH. Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia. Am J Hematol. 2014 Oct;89(10):947-53. Epub 2014 Jul 21. [https://onlinelibrary.wiley.com/doi/10.1002/ajh.23788/full link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4305212/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24944159 PubMed]
## '''Update:''' Brümmendorf TH, Cortes JE, de Souza CA, Guilhot F, Duvillié L, Pavlov D, Gogat K, Countouriotis AM, Gambacorti-Passerini C. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial. Br J Haematol. 2015 Jan;168(1):69-81. Epub 2014 Sep 8. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.13108/full link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4274978/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25196702 PubMed]
<!-- # '''Abstract:''' Jorge E. Cortes, Carlo Gambacorti-Passerini, Michael W.N. Deininger, Michael J. Mauro, Charles Chuah, Dong-Wook Kim, Laurence Reilly, Allison Marianne Jeynes-Ellis, Eric Leip, Nathalie Bardy-Bouxin, Andreas Hochhaus, Tim H. Brümmendorf, and On Behalf of the BFORE Study Investigators. Bosutinib (BOS) versus imatinib (IM) for newly diagnosed chronic myeloid leukemia (CML): Initial results from the BFORE trial. Journal of Clinical Oncology 2017 35:15_suppl, 7002-7002 [http://ascopubs.org/doi/full/10.1200/JCO.2017.35.15_suppl.7002 link to abstract] -->
# '''BFORE:''' Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, Dyagil I, Glushko N, Milojkovic D, le Coutre P, Garcia-Gutierrez V, Reilly L, Jeynes-Ellis A, Leip E, Bardy-Bouxin N, Hochhaus A, Brümmendorf TH. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE Trial. J Clin Oncol. 2018 Jan 20;36(3):231-237. Epub 2017 Nov 1. [http://ascopubs.org/doi/full/10.1200/JCO.2017.74.7162 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29091516 PubMed]

==Cytarabine & Interferon alfa-2b {{#subobject:4a6fe2|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:42b19f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM199707243370402 Guilhot et al. 1997]
|style="background-color:#1a9851"|Phase III (E)
|[[#Interferon_alfa_monotherapy|Interferon alfa-2b]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|[http://www.bloodjournal.org/content/99/5/1527.long Baccarani et al. 2002]
|style="background-color:#1a9851"|Phase III (E)
|[[#Interferon_alfa_monotherapy|Interferon alfa-2b]]
| style="background-color:#1a9850" |Superior MCgR at 24 mo
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa022457 O'Brien et al. 2003 (IRIS)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Imatinib_monotherapy|Imatinib]]
|style="background-color:#d73027"|Inferior FFP
|-
|[https://www.sciencedirect.com/science/article/pii/S0145212602002230 Kühr et al. 2003]
|style="background-color:#1a9851"|Phase III (E)
|Hydrea & IFN alfa-2b
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://link.springer.com/article/10.1007%2Fs00277-006-0186-1 Deenik et al. 2006]
|style="background-color:#1a9851"|Phase III (C)
|HiDAC & IFN
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|}
''Note: IRIS does not specify the type of interferon alfa so this is extrapolated from Guilhot et al. 1997. Many patients on this arm of IRIS crossed over to [[#Imatinib_monotherapy_2|imatinib]]; this experience is summarized in Guilhot et al. 2009.''
====Chemoimmunotherapy====
*[[Cytarabine (Cytosar)]] 20 mg/m<sup>2</sup> (capped at 40 mg in IRIS) SC once per day for 10 days per month
*[[Interferon alfa-2b (Intron-A)]] 5 million units/m<sup>2</sup> SC once per day
**IRIS describes this as the "target dose" (method of dose escalation not specified)

'''Continued indefinitely'''

===References===
# Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau JL, Maloisel F, Bouabdallah R, Guyotat D, Cheron N, Nicolini F, Abgrall JF, Tanzer J; French Chronic Myeloid Leukemia Study Group. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med. 1997 Jul 24;337(4):223-9. [https://www.nejm.org/doi/full/10.1056/NEJM199707243370402 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9227927 PubMed]
# Baccarani M, Rosti G, de Vivo A, Bonifazi F, Russo D, Martinelli G, Testoni N, Amabile M, Fiacchini M, Montefusco E, Saglio G, Tura S; Italian Cooperative Study Group on Myeloid Leukemia. A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia. Blood. 2002 Mar 1;99(5):1527-35. [http://www.bloodjournal.org/content/99/5/1527.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11861264 PubMed]
# '''IRIS:''' O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ; IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003 Mar 13;348(11):994-1004. [https://www.nejm.org/doi/full/10.1056/NEJMoa022457 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12637609 PubMed]
## '''Update:''' Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA; IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006 Dec 7;355(23):2408-17. [https://www.nejm.org/doi/full/10.1056/NEJMoa062867 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17151364 PubMed]
## '''Update:''' Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, Goldman JM, Müller MC, Radich JP, Rudoltz M, Mone M, Gathmann I, Hughes TP, Larson RA; IRIS Investigators. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009 Jun;23(6):1054-61. Epub 2009 Mar 12. Erratum in: Leukemia. 2010 May;24(5):1102. [https://www.nature.com/articles/leu200938 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19282833 PubMed]
## '''Subgroup analysis:''' Guilhot F, Druker B, Larson RA, Gathmann I, So C, Waltzman R, O'Brien SG. High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial. Haematologica. 2009 Dec;94(12):1669-75. Epub 2009 Jul 31. [http://www.haematologica.org/content/94/12/1669.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2791923/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/19648168 PubMed]
## '''Update:''' Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, O'Brien SG, Druker BJ; IRIS Investigators. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017 Mar 9;376(10):917-927. [https://www.nejm.org/doi/full/10.1056/NEJMoa1609324 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28273028 PubMed]
# Kühr T, Burgstaller S, Apfelbeck U, Linkesch W, Seewann H, Fridrik M, Michlmayr G, Krieger O, Lutz D, Lin W, Pont J, Köck L, Abbrederis K, Baldinger C, Buder R, Geissler D, Hausmaninger H, Lang A, Zabernigg A, Duba C, Hilbe W, Eisterer W, Fiegl M, Greil R, Gastl G, Thaler J; Austrian CML Study Group. A randomized study comparing interferon (IFN alpha) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML). Leuk Res. 2003 May;27(5):405-11. [https://www.sciencedirect.com/science/article/pii/S0145212602002230 link to SD article] [https://www.ncbi.nlm.nih.gov/pubmed/12620292 PubMed]
# Deenik W, van der Holt B, Verhoef GE, Schattenberg AV, Verdonck LF, Daenen SM, Zachée P, Westveer PH, Smit WM, Wittebol S, Schouten HC, Löwenberg B, Ossenkoppele GJ, Cornelissen JJ. High-vs low-dose cytarabine combined with interferon alfa in patients with first chronic phase chronic myeloid leukemia: a prospective randomized phase III study. Ann Hematol. 2007 Feb;86(2):117-25. Epub 2006 Oct 10. [https://link.springer.com/article/10.1007%2Fs00277-006-0186-1 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17031690 PubMed]

==Dasatinib monotherapy {{#subobject:88d8e4|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:2dc029|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2815702/ Cortes et al. 2009]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1002315 Kantarjian et al. 2010 (DASISION)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Imatinib_monotherapy|Imatinib]]
|style="background-color:#1a9850"|Superior [[Response_to_treatment#Molecular_response|MMR rate]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3496952/ Radich et al. 2012 (SWOG S0325 Phase 2)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Imatinib_monotherapy|Imatinib]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Dasatinib (Sprycel)]] 100 mg PO once per day

'''Continued indefinitely'''
===References===
<!-- Presented in part at the 50th Annual Meeting of the American Society of Hematology, December 6-9, 2008, San Francisco, CA. -->
# Cortes JE, Jones D, O'Brien S, Jabbour E, Ravandi F, Koller C, Borthakur G, Walker B, Zhao W, Shan J, Kantarjian H. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol. 2010 Jan 20;28(3):398-404. Epub 2009 Dec 14. [http://jco.ascopubs.org/content/28/3/398.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2815702/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20008620 PubMed]
# '''DASISION:''' Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, Moiraghi B, Shen Z, Mayer J, Pasquini R, Nakamae H, Huguet F, Boqué C, Chuah C, Bleickardt E, Bradley-Garelik MB, Zhu C, Szatrowski T, Shapiro D, Baccarani M. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010 Jun 17;362(24):2260-70. Epub 2010 Jun 5. [https://www.nejm.org/doi/full/10.1056/NEJMoa1002315 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20525995 PubMed]
## '''Update:''' Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS, Wang J, Kassack Ipiña JJ, Kim DW, Ogura M, Pavlovsky C, Junghanss C, Milone JH, Nicolini FE, Robak T, Van Droogenbroeck J, Vellenga E, Bradley-Garelik MB, Zhu C, Hochhaus A. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012 Feb 2;119(5):1123-9. Epub 2011 Dec 9. [http://www.bloodjournal.org/content/119/5/1123.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916556/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22160483 PubMed]
## '''Update:''' Jabbour E, Kantarjian HM, Saglio G, Steegmann JL, Shah NP, Boqué C, Chuah C, Pavlovsky C, Mayer J, Cortes J, Baccarani M, Kim DW, Bradley-Garelik MB, Mohamed H, Wildgust M, Hochhaus A. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2014 Jan 23;123(4):494-500. Epub 2013 Dec 5. [http://www.bloodjournal.org/content/123/4/494.full link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190618/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24311723 PubMed]
## '''Subgroup analysis:''' Fujisawa S, Nakamae H, Ogura M, Ishizawa K, Taniwaki M, Utsunomiya A, Matsue K, Takamatsu Y, Usuki K, Tanimoto M, Ishida Y, Akiyama H, Onishi S. Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up. Int J Hematol. 2014 Feb;99(2):141-53. Epub 2013 Dec 20. [http://link.springer.com/article/10.1007%2Fs12185-013-1470-1 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/24357015 PubMed]
## '''Update:''' Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqué C, Shah NP, Chuah C, Casanova L, Bradley-Garelik B, Manos G, Hochhaus A. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. J Clin Oncol. 2016 Jul 10;34(20):2333-40. Epub 2016 May 23. [http://jco.ascopubs.org/content/34/20/2333.full link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5118045/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27217448 PubMed]
# '''SWOG S0325 Phase 2:''' Radich JP, Kopecky KJ, Appelbaum FR, Kamel-Reid S, Stock W, Malnassy G, Paietta E, Wadleigh M, Larson RA, Emanuel P, Tallman M, Lipton J, Turner AR, Deininger M, Druker BJ. A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood. 2012 Nov 8;120(19):3898-905. Epub 2012 Aug 22. [http://www.bloodjournal.org/content/120/19/3898.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3496952/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22915637 PubMed]

==Hydroxyurea & Interferon alfa {{#subobject:917a16|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:909575|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nature.com/articles/2403006 Hehlmann et al. 2003 (CML-Study II)]
|style="background-color:#1a9851"|Phase III (E)
|Hydroxyurea
|style="background-color:#1a9850"|Superior OS
|-
|[http://www.bloodjournal.org/content/109/11/4686.long Hehlmann et al. 2007 (CML-Study III)]
|style="background-color:#1a9851"|Phase III (E)
|Allogeneic HSCT
| style="background-color:#91cf60" |Seems to have superior OS
|-
|[https://www.nature.com/articles/leu2015281 Gratwohl et al. 2015 (CML-Study IIIA)]
|style="background-color:#1a9851"|Phase III (C)
|Allogeneic HSCT
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Of historic interest, and one of the few regimens compared in large RCTs against allogeneic HSCT.''
====Chemoimmunotherapy====
*[[Hydroxyurea (Hydrea)]]
*[[:Category:Interferons|Interferon alfa]]

===References===
# '''CML-Study II:''' Hehlmann R, Berger U, Pfirrmann M, Hochhaus A, Metzgeroth G, Maywald O, Hasford J, Reiter A, Hossfeld DK, Kolb HJ, Löffler H, Pralle H, Queisser W, Griesshammer M, Nerl C, Kuse R, Tobler A, Eimermacher H, Tichelli A, Aul C, Wilhelm M, Fischer JT, Perker M, Scheid C, Schenk M, Weiss J, Meier CR, Kremers S, Labedzki L, Schmeiser T, Lohrmann HP, Heimpel H; German CML-Study Group. Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea. Leukemia. 2003 Aug;17(8):1529-37. [https://www.nature.com/articles/2403006 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12886239 PubMed]
# '''CML-Study III:''' Hehlmann R, Berger U, Pfirrmann M, Heimpel H, Hochhaus A, Hasford J, Kolb HJ, Lahaye T, Maywald O, Reiter A, Hossfeld DK, Huber C, Löffler H, Pralle H, Queisser W, Tobler A, Nerl C, Solenthaler M, Goebeler ME, Griesshammer M, Fischer T, Kremers S, Eimermacher H, Pfreundschuh M, Hirschmann WD, Lechner K, Wassmann B, Falge C, Kirchner HH, Gratwohl A. Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood. 2007 Jun 1;109(11):4686-92. Epub 2007 Feb 22. [http://www.bloodjournal.org/content/109/11/4686.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17317858 PubMed]
# '''CML-Study IIIA:''' Gratwohl A, Pfirrmann M, Zander A, Kröger N, Beelen D, Novotny J, Nerl C, Scheid C, Spiekermann K, Mayer J, Sayer HG, Falge C, Bunjes D, Döhner H, Ganser A, Schmidt-Wolf I, Schwerdtfeger R, Baurmann H, Kuse R, Schmitz N, Wehmeier A, Fischer JT, Ho AD, Wilhelm M, Goebeler ME, Lindemann HW, Bormann M, Hertenstein B, Schlimok G, Baerlocher GM, Aul C, Pfreundschuh M, Fabian M, Staib P, Edinger M, Schatz M, Fauser A, Arnold R, Kindler T, Wulf G, Rosselet A, Hellmann A, Schäfer E, Prümmer O, Schenk M, Hasford J, Heimpel H, Hossfeld DK, Kolb HJ, Büsche G, Haferlach C, Schnittger S, Müller MC, Reiter A, Berger U, Saußele S, Hochhaus A, Hehlmann R; SAKK; German CML Study Group. Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment. Leukemia. 2016 Mar;30(3):562-9. Epub 2015 Oct 14. [https://www.nature.com/articles/leu2015281 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26464170 PubMed]

==Imatinib monotherapy {{#subobject:917a16|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:909575|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa022457 O'Brien et al. 2003 (IRIS)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Cytarabine_.26_Interferon_alfa-2b|Cytarabine & Interferon alfa]]
|style="background-color:#1a9850"|Superior FFP
|-
|[http://www.bloodjournal.org/content/108/6/1835.long Kantarjian et al. 2006]
|style="background-color:#ffffbe"|Retrospective
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[http://www.bloodjournal.org/content/113/19/4497.long Baccarani et al. 2009 (GIMEMA CML/022)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Imatinib_monotherapy.2C_high_dose|High-dose imatinib]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1002315 Kantarjian et al. 2010 (DASISION)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Dasatinib_monotherapy|Dasatinib]]
|style="background-color:#d73027"|Inferior [[Response_to_treatment#Molecular_response|MMR rate]]
|-
|rowspan=2|[https://www.nejm.org/doi/full/10.1056/NEJMoa0912614 Saglio et al. 2010 (ENESTnd)]
|rowspan=2 style="background-color:#1a9851"|Phase III (C)
|1. [[#Nilotinib_monotherapy|Nilotinib 300 mg twice per day]]
|style="background-color:#fc8d59"|Seems to have inferior TTP
|-
|2. [[#Nilotinib_monotherapy|Nilotinib 400 mg twice per day]]
|style="background-color:#d73027"|Inferior TTP
|-
|rowspan=3|[https://www.nejm.org/doi/full/10.1056/NEJMoa1004095 Preudhomme et al. 2010 (SPIRIT)]
|rowspan=3 style="background-color:#1a9851"|Phase III (C)
|1. Imatinib 600 mg daily
|style="background-color:#d3d3d3"|Not reported
|-
|2. [[#Imatinib_.26_Interferon_alfa-2a|Imatinib & Interferon alfa]]
|style="background-color:#d73027"|Inferior [[Response_to_treatment#Molecular_response|MMR rate]] at 12 months
|-
|3. [[#Imatinib_.26_LoDAC|Imatinib & LoDAC]]
|style="background-color:#d3d3d3"|Not reported
|-
|rowspan=2|[http://jco.ascopubs.org/content/29/12/1634.long Hehlmann et al. 2011 (CML-Study IV)]
|rowspan=2 style="background-color:#1a9851"|Phase III (C)
|1. [[#Imatinib_monotherapy.2C_high_dose|High-dose imatinib]]
|style="background-color:#d73027"|Inferior [[Response_to_treatment#Molecular_response|MMR rate]] at 12 months
|-
|2. [[#Imatinib_.26_Interferon_alfa-2a|Imatinib & Interferon alfa]]
|style="background-color:#d3d3d3"|Not reported
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979199/ Cortes et al. 2012 (BELA)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Bosutinib_monotherapy|Bosutinib]]
|style="background-color:#d73027"|Inferior [[Response_to_treatment#Molecular_response|MMR rate]] at 12 months
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3496952/ Radich et al. 2012 (SWOG S0325 Phase 2)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Dasatinib_monotherapy|Dasatinib]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4127316/ Deininger et al. 2013 (SWOG S0325 Phase 1)]
|style="background-color:#1a9851"|Randomized Phase II (C)
|[[#Imatinib_monotherapy.2C_high_dose|High-dose imatinib]]
|style="background-color:#fc8d59"|Seems to have inferior [[Response_to_treatment#Molecular_response|MMR rate]] at 12 months
|-
|[http://www.bloodjournal.org/content/124/5/729.long Hughes et al. 2014 (ENESTcmr)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5161008/ Yeung et al. 2014 (TIDEL-II)]
|style="background-color:#91cf61"|Non-randomized
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4416528/ Wang et al. 2015 (ENESTchina)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Nilotinib_monotherapy|Nilotinib]]
|style="background-color:#d73027"|Inferior [[Response_to_treatment#Molecular_response|MMR rate]] at 12 months
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)00080-2/fulltext Lipton et al. 2016 (EPIC<sub>CML</sub>)]
|style="background-color:#1a9851"|Phase III (C)
|Ponatinib
|style="background-color:#fee08b"|Might have inferior [[Response_to_treatment#Molecular_response|MMR rate]] at 12 months
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2017.74.7162 Cortes et al. 2017 (BFORE)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Bosutinib_monotherapy|Bosutinib]]
|style="background-color:#fc8d59"|Seems to have inferior [[Response_to_treatment#Molecular_response|MMR rate]] at 12 months
|-
|rowspan=2|[http://clincancerres.aacrjournals.org/content/23/23/7180.long Kwak et al. 2017 (RERISE)]
|rowspan=2 style="background-color:#1a9851"|Phase III (C)
|1. [[#Radotinib_monotherapy|Radotinib 300 mg twice per day]]
|style="background-color:#d73027"|Inferior [[Response_to_treatment#Molecular_response|MMR rate]] at 12 months
|-
|2. [[#Radotinib_monotherapy|Radotinib 400 mg twice per day]]
|style="background-color:#fc8d59"|Seems to have inferior [[Response_to_treatment#Molecular_response|MMR rate]] at 12 months
|-
|}
''Note: EPIC was terminated early, "following concerns about vascular adverse events observed in patients given ponatinib in other trials;" it should not be confused with the trial by the same name in colorectal cancer.''
====Chemotherapy====
*[[Imatinib (Gleevec)]] 400 mg PO once per day

'''Continued indefinitely'''
====Subsequent treatment====
*ENESTcmr, patients with detectable BCR-ABL1 after at least 2 years of therapy: [[#Imatinib_monotherapy_2|continued imatinib]] versus [[#Nilotinib_monotherapy_2|nilotinib]]
*TIDEL-II: Patients failing to meet molecular targets were either dose-increased to [[#Imatinib_monotherapy_2|imatinib 800 mg per day]] and then switched to [[#Nilotinib_monotherapy_2|nilotinib]] 3 months later if they were still failing to meet targets, or switched to [[#Nilotinib_monotherapy_2|nilotinib]] directly. This was not a randomization.

===References===
# '''IRIS:''' O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ; IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003 Mar 13;348(11):994-1004. [https://www.nejm.org/doi/full/10.1056/NEJMoa022457 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12637609 PubMed]
## '''Update:''' Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA; IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006 Dec 7;355(23):2408-17. [https://www.nejm.org/doi/full/10.1056/NEJMoa062867 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17151364 PubMed]
## '''Update:''' Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, Goldman JM, Müller MC, Radich JP, Rudoltz M, Mone M, Gathmann I, Hughes TP, Larson RA; IRIS Investigators. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009 Jun;23(6):1054-61. Epub 2009 Mar 12. Erratum in: Leukemia. 2010 May;24(5):1102. [https://www.nature.com/articles/leu200938 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19282833 PubMed]
## '''Subgroup analysis:''' Guilhot F, Druker B, Larson RA, Gathmann I, So C, Waltzman R, O'Brien SG. High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial. Haematologica. 2009 Dec;94(12):1669-75. Epub 2009 Jul 31. [http://www.haematologica.org/content/94/12/1669.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2791923/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/19648168 PubMed]
## '''Update:''' Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, O'Brien SG, Druker BJ; IRIS Investigators. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017 Mar 9;376(10):917-927. [https://www.nejm.org/doi/full/10.1056/NEJMoa1609324 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28273028 PubMed]
# '''Retrospective:''' Kantarjian HM, Talpaz M, O'Brien S, Jones D, Giles F, Garcia-Manero G, Faderl S, Ravandi F, Rios MB, Shan J, Cortes J. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood. 2006 Sep 15;108(6):1835-40. Epub 2006 May 18. [http://www.bloodjournal.org/content/108/6/1835.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16709931 PubMed] content property of [http://hemonc.org HemOnc.org] 
# '''GIMEMA CML/022:''' Baccarani M, Rosti G, Castagnetti F, Haznedaroglu I, Porkka K, Abruzzese E, Alimena G, Ehrencrona H, Hjorth-Hansen H, Kairisto V, Levato L, Martinelli G, Nagler A, Lanng Nielsen J, Ozbek U, Palandri F, Palmieri F, Pane F, Rege-Cambrin G, Russo D, Specchia G, Testoni N, Weiss-Bjerrum O, Saglio G, Simonsson B. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood. 2009 May 7;113(19):4497-504. Epub 2009 Mar 4. [http://www.bloodjournal.org/content/113/19/4497.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19264678 PubMed]
## '''Update:''' Castagnetti F, Gugliotta G, Breccia M, Stagno F, Iurlo A, Albano F, Abruzzese E, Martino B, Levato L, Intermesoli T, Pregno P, Rossi G, Gherlinzoni F, Leoni P, Cavazzini F, Venturi C, Soverini S, Testoni N, Alimena G, Cavo M, Martinelli G, Pane F, Saglio G, Rosti G, Baccarani M; GIMEMA CML Working Party. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. Leukemia. 2015 Sep;29(9):1823-31. Epub 2015 Jun 19. [https://www.nature.com/leu/journal/v29/n9/full/leu2015152a.html link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26088952 PubMed]
# '''DASISION:''' Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, Moiraghi B, Shen Z, Mayer J, Pasquini R, Nakamae H, Huguet F, Boqué C, Chuah C, Bleickardt E, Bradley-Garelik MB, Zhu C, Szatrowski T, Shapiro D, Baccarani M. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010 Jun 17;362(24):2260-70. Epub 2010 Jun 5. [https://www.nejm.org/doi/full/10.1056/NEJMoa1002315 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20525995 PubMed]
## '''Update:''' Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS, Wang J, Kassack Ipiña JJ, Kim DW, Ogura M, Pavlovsky C, Junghanss C, Milone JH, Nicolini FE, Robak T, Van Droogenbroeck J, Vellenga E, Bradley-Garelik MB, Zhu C, Hochhaus A. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012 Feb 2;119(5):1123-9. Epub 2011 Dec 9. [http://www.bloodjournal.org/content/119/5/1123.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916556/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22160483 PubMed]
## '''Update:''' Jabbour E, Kantarjian HM, Saglio G, Steegmann JL, Shah NP, Boqué C, Chuah C, Pavlovsky C, Mayer J, Cortes J, Baccarani M, Kim DW, Bradley-Garelik MB, Mohamed H, Wildgust M, Hochhaus A. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2014 Jan 23;123(4):494-500. Epub 2013 Dec 5. [http://www.bloodjournal.org/content/123/4/494.full link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190618/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24311723 PubMed]
## '''Subgroup analysis:''' Fujisawa S, Nakamae H, Ogura M, Ishizawa K, Taniwaki M, Utsunomiya A, Matsue K, Takamatsu Y, Usuki K, Tanimoto M, Ishida Y, Akiyama H, Onishi S. Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up. Int J Hematol. 2014 Feb;99(2):141-53. Epub 2013 Dec 20. [http://link.springer.com/article/10.1007%2Fs12185-013-1470-1 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/24357015 PubMed]
## '''Update:''' Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqué C, Shah NP, Chuah C, Casanova L, Bradley-Garelik B, Manos G, Hochhaus A. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. J Clin Oncol. 2016 Jul 10;34(20):2333-40. Epub 2016 May 23. [http://jco.ascopubs.org/content/34/20/2333.full link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5118045/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27217448 PubMed]
# '''ENESTnd:''' Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM; ENESTnd Investigators. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010 Jun 17;362(24):2251-9. Epub 2010 Jun 5. [https://www.nejm.org/doi/full/10.1056/NEJMoa0912614 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20525993 PubMed]
## '''Update:''' Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, Goh YT, Rosti G, Nakamae H, Gallagher NJ, Hoenekopp A, Blakesley RE, Larson RA, Hughes TP. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011 Sep;12(9):841-51. Epub 2011 Aug 17. Erratum in: Lancet Oncol. 2011 Oct;12(11):989. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70201-7/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21856226 PubMed]
## '''Update:''' Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, Kim DW, Flinn IW, Kurokawa M, Moiraghi B, Yu R, Blakesley RE, Gallagher NJ, Saglio G, Kantarjian HM. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia. 2012 Oct;26(10):2197-203. Epub 2012 May 18. [https://www.nature.com/leu/journal/v26/n10/full/leu2012134a.html?WT.ec_id=LEU-201210 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22699418 PubMed]
<!-- ## '''Update: Abstract:''' Hughes TP, le Coutre PD, Jootar S, et al. ENESTnd 5-year follow-up: continued benefit of frontline nilotinib (NIL) compared with imatinib (IM) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) [abstract]. Haematologica. 2014. 99. Abstract s677. -->
## '''Update:''' Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre PD, Etienne G, Dorlhiac-Llacer PE, Clark RE, Flinn IW, Nakamae H, Donohue B, Deng W, Dalal D, Menssen HD, Kantarjian HM. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016 May;30(5):1044-54. Epub 2016 Feb 3. [https://www.nature.com/leu/journal/v30/n5/full/leu20165a.html link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4858585/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26837842 PubMed]
<!-- Presented in part at the annual meeting of the American Society of Hematology, New Orleans, December 7, 2009. -->
# '''SPIRIT:''' Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, Maloisel F, Coiteux V, Gardembas M, Berthou C, Vekhoff A, Rea D, Jourdan E, Allard C, Delmer A, Rousselot P, Legros L, Berger M, Corm S, Etienne G, Roche-Lestienne C, Eclache V, Mahon FX, Guilhot F; SPIRIT Investigators; France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC). Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med. 2010 Dec 23;363(26):2511-21. [https://www.nejm.org/doi/full/10.1056/NEJMoa1004095 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21175313 PubMed]
<!-- Presented in part at the 51st Annual Meeting of the American Society of Hematology, New Orleans, LA, December 5-8, 2009; at the 46th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 4-7, 2010; and at the Annual Meeting of the European Hematology Association, Barcelona, Spain, June 9-11, 2010. -->
# '''CML-Study IV:''' Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, Müller MC, Pletsch N, Proetel U, Haferlach C, Schlegelberger B, Balleisen L, Hänel M, Pfirrmann M, Krause SW, Nerl C, Pralle H, Gratwohl A, Hossfeld DK, Hasford J, Hochhaus A, Saussele S. Tolerability-adapted imatinib 800 mg/day versus 400 mg/day versus 400 mg/day plus interferon-a in newly diagnosed chronic myeloid leukemia. J Clin Oncol. 2011 Apr 20;29(12):1634-42. Epub 2011 Mar 21. [http://jco.ascopubs.org/content/29/12/1634.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21422420 PubMed] 
## '''Update:''' Hehlmann R, Müller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A, Proetel U, Pletsch N, Pfirrmann M, Haferlach C, Schnittger S, Einsele H, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Ehninger G, Heim D, Heimpel H, Nerl C, Krause SW, Hossfeld DK, Kolb HJ, Hasford J, Saußele S, Hochhaus A. Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV. J Clin Oncol. 2014 Feb 10;32(5):415-23. Epub 2013 Dec 2. [http://jco.ascopubs.org/content/32/5/415.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24297946 PubMed]
## '''Update:''' Kalmanti L, Saussele S, Lauseker M, Müller MC, Dietz CT, Heinrich L, Hanfstein B, Proetel U, Fabarius A, Krause SW, Rinaldetti S, Dengler J, Falge C, Oppliger-Leibundgut E, Burchert A, Neubauer A, Kanz L, Stegelmann F, Pfreundschuh M, Spiekermann K, Scheid C, Pfirrmann M, Hochhaus A, Hasford J, Hehlmann R. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia. 2015 May;29(5):1123-32. Epub 2015 Feb 13. [https://www.nature.com/leu/journal/v29/n5/full/leu201536a.html link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25676422 PubMed]
## '''Update:''' Hehlmann R, Lauseker M, Saußele S, Pfirrmann M, Krause S, Kolb HJ, Neubauer A, Hossfeld DK, Nerl C, Gratwohl A, Baerlocher GM, Heim D, Brümmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Müller MC, Jeromin S, Proetel U, Kohlbrenner K, Voskanyan A, Rinaldetti S, Seifarth W, Spieß B, Balleisen L, Goebeler MC, Hänel M, Ho A, Dengler J, Falge C, Kanz L, Kremers S, Burchert A, Kneba M, Stegelmann F, Köhne CA, Lindemann HW, Waller CF, Pfreundschuh M, Spiekermann K, Berdel WE, Müller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Pezzutto A, Schenk M, Brossart P, Geer T, Bildat S, Schäfer E, Hochhaus A, Hasford J. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017 Nov;31(11):2398-2406. Epub 2017 Aug 14. [https://www.nature.com/leu/journal/v31/n11/full/leu2017253a.html link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28804124 PubMed]
# '''BELA:''' Cortes JE, Kim DW, Kantarjian HM, Brümmendorf TH, Dyagil I, Griskevicius L, Malhotra H, Powell C, Gogat K, Countouriotis AM, Gambacorti-Passerini C. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012 Oct 1;30(28):3486-92. Epub 2012 Sep 4. [http://jco.ascopubs.org/content/30/28/3486.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979199/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22949154 PubMed]
## '''Update:''' Gambacorti-Passerini C, Cortes JE, Lipton JH, Dmoszynska A, Wong RS, Rossiev V, Pavlov D, Gogat Marchant K, Duvillié L, Khattry N, Kantarjian HM, Brümmendorf TH. Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia. Am J Hematol. 2014 Oct;89(10):947-53. Epub 2014 Jul 21. [https://onlinelibrary.wiley.com/doi/10.1002/ajh.23788/full link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4305212/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24944159 PubMed]
## '''Update:''' Brümmendorf TH, Cortes JE, de Souza CA, Guilhot F, Duvillié L, Pavlov D, Gogat K, Countouriotis AM, Gambacorti-Passerini C. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial. Br J Haematol. 2015 Jan;168(1):69-81. Epub 2014 Sep 8. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.13108/full link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4274978/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25196702 PubMed]
# '''SWOG S0325 Phase 2:''' Radich JP, Kopecky KJ, Appelbaum FR, Kamel-Reid S, Stock W, Malnassy G, Paietta E, Wadleigh M, Larson RA, Emanuel P, Tallman M, Lipton J, Turner AR, Deininger M, Druker BJ. A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood. 2012 Nov 8;120(19):3898-905. Epub 2012 Aug 22. [http://www.bloodjournal.org/content/120/19/3898.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3496952/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22915637 PubMed]
<!-- Results presented in part by Dr. Jerald Radich at the annual meeting of the American Society of Hematology (December 4–7, 2010, Orlando, FL) -->
# '''SWOG S0325 Phase 1:''' Deininger MW, Kopecky KJ, Radich JP, Kamel-Reid S, Stock W, Paietta E, Emanuel PD, Tallman M, Wadleigh M, Larson RA, Lipton JH, Slovak ML, Appelbaum FR, Druker BJ. Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized phase II trial in newly diagnosed chronic phase chronic myeloid leukaemia. Br J Haematol. 2014 Jan;164(2):223-32. Epub 2013 Nov 4. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.12618/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4127316/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24383843 PubMed]
# '''ENESTcmr:''' Hughes TP, Lipton JH, Spector N, Cervantes F, Pasquini R, Clementino NC, Dorlhiac Llacer PE, Schwarer AP, Mahon FX, Rea D, Branford S, Purkayastha D, Collins L, Szczudlo T, Leber B. Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib. Blood. 2014 Jul 31;124(5):729-36. Epub 2014 Jun 19. [http://www.bloodjournal.org/content/124/5/729.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24948656/ PubMed]
## '''Update:''' Hughes TP, Leber B, Cervantes F, Spector N, Pasquini R, Clementino NCD, Schwarer AP, Dorlhiac-Llacer PE, Mahon FX, Rea D, Guerci-Bresler A, Kamel-Reid S, Bendit I, Acharya S, Glynos T, Dalal D, Branford S, Lipton JH. Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results. Leukemia. 2017 Nov;31(11):2529-2531. Epub 2017 Aug 3. [https://www.nature.com/articles/leu2017247 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668492/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/28862704 PubMed]
<!-- Presented in part at the 52nd annual meeting of the American Society of Hematology (ASH), Orlando, FL, December 4-7, 2010; 53rd annual meeting of the ASH, San Diego CA, December 10-13, 2011; and the 54th annual meeting of the ASH, Atlanta, GA, December 8-11, 2012. Also presented at the 16th Congress of the European Hematology Association (EHA), London, United Kingdom, June 9-12, 2011. -->
# '''TIDEL-II:''' Yeung DT, Osborn MP, White DL, Branford S, Braley J, Herschtal A, Kornhauser M, Issa S, Hiwase DK, Hertzberg M, Schwarer AP, Filshie R, Arthur CK, Kwan YL, Trotman J, Forsyth CJ, Taper J, Ross DM, Beresford J, Tam C, Mills AK, Grigg AP, Hughes TP; Australasian Leukaemia and Lymphoma Group. TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. Blood. 2015 Feb 5;125(6):915-23. Epub 2014 Dec 17. [http://www.bloodjournal.org/content/125/6/915.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5161008/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25519749 PubMed]
# '''ENESTchina:''' Wang J, Shen ZX, Saglio G, Jin J, Huang H, Hu Y, Du X, Li J, Meng F, Zhu H, Hu J, Wang J, Hou M, Hertle S, Menssen HD, Ortmann CE, Tribouley C, Yuan Y, Baccarani M, Huang X. Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina. Blood. 2015 Apr 30;125(18):2771-8. Epub 2015 Mar 12. [http://www.bloodjournal.org/content/125/18/2771.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4416528/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25766724 PubMed]
# '''EPIC:''' Lipton JH, Chuah C, Guerci-Bresler A, Rosti G, Simpson D, Assouline S, Etienne G, Nicolini FE, le Coutre P, Clark RE, Stenke L, Andorsky D, Oehler V, Lustgarten S, Rivera VM, Clackson T, Haluska FG, Baccarani M, Cortes JE, Guilhot F, Hochhaus A, Hughes T, Kantarjian HM, Shah NP, Talpaz M, Deininger MW; EPIC investigators. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2016 May;17(5):612-21. Epub 2016 Apr 12. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)00080-2/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27083332 PubMed]
<!-- # '''Abstract:''' Jorge E. Cortes, Carlo Gambacorti-Passerini, Michael W.N. Deininger, Michael J. Mauro, Charles Chuah, Dong-Wook Kim, Laurence Reilly, Allison Marianne Jeynes-Ellis, Eric Leip, Nathalie Bardy-Bouxin, Andreas Hochhaus, Tim H. Brümmendorf, and On Behalf of the BFORE Study Investigators. Bosutinib (BOS) versus imatinib (IM) for newly diagnosed chronic myeloid leukemia (CML): Initial results from the BFORE trial. Journal of Clinical Oncology 2017 35:15_suppl, 7002-7002 [http://ascopubs.org/doi/full/10.1200/JCO.2017.35.15_suppl.7002 link to abstract] -->
# '''BFORE:''' Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, Dyagil I, Glushko N, Milojkovic D, le Coutre P, Garcia-Gutierrez V, Reilly L, Jeynes-Ellis A, Leip E, Bardy-Bouxin N, Hochhaus A, Brümmendorf TH. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE Trial. J Clin Oncol. 2018 Jan 20;36(3):231-237. Epub 2017 Nov 1. [http://ascopubs.org/doi/full/10.1200/JCO.2017.74.7162 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29091516 PubMed]
# '''RERISE:''' Kwak JY, Kim SH, Oh SJ, Zang DY, Kim H, Kim JA, Do YR, Kim HJ, Park JS, Choi CW, Lee WS, Mun YC, Kong JH, Chung JS, Shin HJ, Kim DY, Park J, Jung CW, Bunworasate U, Comia NS, Jootar S, Reksodiputro AH, Caguioa PB, Lee SE, Kim DW. Phase III clinical trial (RERISE study) results of efficacy and safety of radotinib compared with imatinib in newly diagnosed chronic phase chronic myeloid leukemia. Clin Cancer Res. 2017 Dec 1;23(23):7180-7188. Epub 2017 Sep 22. [http://clincancerres.aacrjournals.org/content/23/23/7180.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28939746 PubMed]

==Imatinib monotherapy, high dose {{#subobject:5b2d07|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:a9a61c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.bloodjournal.org/content/113/15/3428.long Castagnetti et al. 2009 (GIMEMA CML/021)]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[http://www.bloodjournal.org/content/113/19/4497.long Baccarani et al. 2009 (GIMEMA CML/022)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Imatinib_monotherapy|Standard-dose imatinib]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979244/ Cortes et al. 2010]
|style="background-color:#1a9851"|Phase III (E)
|[[#Imatinib_monotherapy|Standard-dose imatinib]]
|style="background-color:#ffffbf"|Seems not superior
|-
|rowspan=2|[http://jco.ascopubs.org/content/29/12/1634.long Hehlmann et al. 2011 (CML-Study IV)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[#Imatinib_monotherapy|Standard-dose imatinib]]
|style="background-color:#1a9850"|Superior [[Response_to_treatment#Molecular_response|MMR rate]] at 12 months
|-
|2. [[#Imatinib_.26_Interferon_alfa-2a|Imatinib & Interferon alfa]]
|style="background-color:#1a9850"|Superior [[Response_to_treatment#Molecular_response|MMR rate]] at 12 months
|-
|[https://link.springer.com/article/10.1007%2Fs00277-013-1730-4 Thielen et al. 2013]
|style="background-color:#1a9851"|Phase III (C)
|Cytarabine & HD-Imatinib
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4127316/ Deininger et al. 2013 (SWOG S0325 Phase 1)]
|style="background-color:#1a9851"|Randomized Phase II (E)
|[[#Imatinib_monotherapy|Standard-dose imatinib]]
|style="background-color:#91cf60"|Seems to have superior [[Response_to_treatment#Molecular_response|MMR rate]] at 12 months
|-
|}

''Note: GIMEMA CML/021 used a lead-in dose of 400 mg PO once per day for 2 weeks, followed by escalation to 400 mg PO twice per day.''
====Chemotherapy====
*[[Imatinib (Gleevec)]] 800 mg PO once per day (CML-Study IV) or 400 mg PO twice per day (S0325, GIMEMA studies)

'''Continued indefinitely'''

===References===
# '''GIMEMA CML/021:''' Castagnetti F, Palandri F, Amabile M, Testoni N, Luatti S, Soverini S, Iacobucci I, Breccia M, Rege Cambrin G, Stagno F, Specchia G, Galieni P, Iuliano F, Pane F, Saglio G, Alimena G, Martinelli G, Baccarani M, Rosti G; GIMEMA CML Working Party. Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party. Blood. 2009 Apr 9;113(15):3428-34. Epub 2009 Feb 11. [http://www.bloodjournal.org/content/113/15/3428.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19211938 PubMed]
## '''Update:''' Castagnetti F, Gugliotta G, Breccia M, Stagno F, Iurlo A, Albano F, Abruzzese E, Martino B, Levato L, Intermesoli T, Pregno P, Rossi G, Gherlinzoni F, Leoni P, Cavazzini F, Venturi C, Soverini S, Testoni N, Alimena G, Cavo M, Martinelli G, Pane F, Saglio G, Rosti G, Baccarani M; GIMEMA CML Working Party. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. Leukemia. 2015 Sep;29(9):1823-31. Epub 2015 Jun 19. [https://www.nature.com/leu/journal/v29/n9/full/leu2015152a.html link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26088952 PubMed]
# '''GIMEMA CML/022:''' Baccarani M, Rosti G, Castagnetti F, Haznedaroglu I, Porkka K, Abruzzese E, Alimena G, Ehrencrona H, Hjorth-Hansen H, Kairisto V, Levato L, Martinelli G, Nagler A, Lanng Nielsen J, Ozbek U, Palandri F, Palmieri F, Pane F, Rege-Cambrin G, Russo D, Specchia G, Testoni N, Weiss-Bjerrum O, Saglio G, Simonsson B. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood. 2009 May 7;113(19):4497-504. Epub 2009 Mar 4. [http://www.bloodjournal.org/content/113/19/4497.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19264678 PubMed]
## '''Update:''' Castagnetti F, Gugliotta G, Breccia M, Stagno F, Iurlo A, Albano F, Abruzzese E, Martino B, Levato L, Intermesoli T, Pregno P, Rossi G, Gherlinzoni F, Leoni P, Cavazzini F, Venturi C, Soverini S, Testoni N, Alimena G, Cavo M, Martinelli G, Pane F, Saglio G, Rosti G, Baccarani M; GIMEMA CML Working Party. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. Leukemia. 2015 Sep;29(9):1823-31. Epub 2015 Jun 19. [https://www.nature.com/leu/journal/v29/n9/full/leu2015152a.html link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26088952 PubMed]
# Cortes JE, Baccarani M, Guilhot F, Druker BJ, Branford S, Kim DW, Pane F, Pasquini R, Goldberg SL, Kalaycio M, Moiraghi B, Rowe JM, Tothova E, De Souza C, Rudoltz M, Yu R, Krahnke T, Kantarjian HM, Radich JP, Hughes TP. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol. 2010 Jan 20;28(3):424-30. Epub 2009 Dec 14. Erratum in: J Clin Oncol. 2010 May 1;28(13):2314. [http://ascopubs.org/doi/full/10.1200/JCO.2009.25.3724 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979244/ link to PMC article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20008622 PubMed]
<!-- Presented in part at the 51st Annual Meeting of the American Society of Hematology, New Orleans, LA, December 5-8, 2009; at the 46th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 4-7, 2010; and at the Annual Meeting of the European Hematology Association, Barcelona, Spain, June 9-11, 2010. -->
# '''CML-Study IV:''' Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, Müller MC, Pletsch N, Proetel U, Haferlach C, Schlegelberger B, Balleisen L, Hänel M, Pfirrmann M, Krause SW, Nerl C, Pralle H, Gratwohl A, Hossfeld DK, Hasford J, Hochhaus A, Saussele S. Tolerability-adapted imatinib 800 mg/day versus 400 mg/day versus 400 mg/day plus interferon-a in newly diagnosed chronic myeloid leukemia. J Clin Oncol. 2011 Apr 20;29(12):1634-42. Epub 2011 Mar 21. [http://jco.ascopubs.org/content/29/12/1634.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21422420 PubMed] 
## '''Update:''' Hehlmann R, Müller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A, Proetel U, Pletsch N, Pfirrmann M, Haferlach C, Schnittger S, Einsele H, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Ehninger G, Heim D, Heimpel H, Nerl C, Krause SW, Hossfeld DK, Kolb HJ, Hasford J, Saußele S, Hochhaus A. Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV. J Clin Oncol. 2014 Feb 10;32(5):415-23. Epub 2013 Dec 2. [http://jco.ascopubs.org/content/32/5/415.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24297946 PubMed]
## '''Update:''' Kalmanti L, Saussele S, Lauseker M, Müller MC, Dietz CT, Heinrich L, Hanfstein B, Proetel U, Fabarius A, Krause SW, Rinaldetti S, Dengler J, Falge C, Oppliger-Leibundgut E, Burchert A, Neubauer A, Kanz L, Stegelmann F, Pfreundschuh M, Spiekermann K, Scheid C, Pfirrmann M, Hochhaus A, Hasford J, Hehlmann R. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia. 2015 May;29(5):1123-32. Epub 2015 Feb 13. [https://www.nature.com/leu/journal/v29/n5/full/leu201536a.html link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25676422 PubMed]
## '''Update:''' Hehlmann R, Lauseker M, Saußele S, Pfirrmann M, Krause S, Kolb HJ, Neubauer A, Hossfeld DK, Nerl C, Gratwohl A, Baerlocher GM, Heim D, Brümmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Müller MC, Jeromin S, Proetel U, Kohlbrenner K, Voskanyan A, Rinaldetti S, Seifarth W, Spieß B, Balleisen L, Goebeler MC, Hänel M, Ho A, Dengler J, Falge C, Kanz L, Kremers S, Burchert A, Kneba M, Stegelmann F, Köhne CA, Lindemann HW, Waller CF, Pfreundschuh M, Spiekermann K, Berdel WE, Müller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Pezzutto A, Schenk M, Brossart P, Geer T, Bildat S, Schäfer E, Hochhaus A, Hasford J. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017 Nov;31(11):2398-2406. Epub 2017 Aug 14. [https://www.nature.com/leu/journal/v31/n11/full/leu2017253a.html link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28804124 PubMed]
# Thielen N, van der Holt B, Verhoef GE, Ammerlaan RA, Sonneveld P, Janssen JJ, Deenik W, Falkenburg JH, Kersten MJ, Sinnige HA, Schipperus M, Schattenberg A, van Marwijk Kooy R, Smit WM, Chu IW, Valk PJ, Ossenkoppele GJ, Cornelissen JJ. High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group. Ann Hematol. 2013 Aug;92(8):1049-56. Epub 2013 Apr 10. [https://link.springer.com/article/10.1007%2Fs00277-013-1730-4 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23572137 PubMed]
<!-- Results presented in part by Dr. Jerald Radich at the annual meeting of the American Society of Hematology (December 4–7, 2010, Orlando, FL) -->
# '''SWOG S0325:''' Deininger MW, Kopecky KJ, Radich JP, Kamel-Reid S, Stock W, Paietta E, Emanuel PD, Tallman M, Wadleigh M, Larson RA, Lipton JH, Slovak ML, Appelbaum FR, Druker BJ. Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized phase II trial in newly diagnosed chronic phase chronic myeloid leukaemia. Br J Haematol. 2014 Jan;164(2):223-32. Epub 2013 Nov 4. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.12618/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4127316/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24383843 PubMed]

==Imatinib monotherapy, intermittent therapy {{#subobject:cc55a5|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:8cb301|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.bloodjournal.org/content/121/26/5138.long Russo et al. 2013]
|style="background-color:#91cf61"|Phase II
|-
|}
''Eligible patients had been taking imatinib for at least two years and were in a complete cytogenetic response''
====Chemotherapy====
*[[Imatinib (Gleevec)]] any "standard dose" PO once per day as follows:
**Weeks 1 to 4: 1 week on, 1 week off
**Weeks 5 to 12: 2 weeks on, 2 weeks off
**Week 13 onwards: 1 month on, 1 month off

'''Treatment continues indefinitely or until loss of complete cytogenetic response is observed. Patients who lost major molecular response could go back to once per day therapy after the first year.'''

===References===
# Russo D, Martinelli G, Malagola M, Skert C, Soverini S, Iacobucci I, De Vivo A, Testoni N, Castagnetti F, Gugliotta G, Turri D, Bergamaschi M, Pregno P, Pungolino E, Stagno F, Breccia M, Martino B, Intermesoli T, Fava C, Abruzzese E, Tiribelli M, Bigazzi C, Cesana BM, Rosti G, Baccarani M. Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. Blood. 2013 Jun 27;121(26):5138-44. Epub 2013 May 15. [http://www.bloodjournal.org/content/121/26/5138.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23678005 PubMed]

==Imatinib monotherapy, planned discontinuation {{#subobject:54d105|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Variant #1, ; Mahon et al. 2013 (STIM2) {{#subobject:b828ff|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(10)70233-3/fulltext Mahon et al. 2010 (STIM1)]
|style="background-color:#91cf61"|Phase II
|-
|[http://www.bloodjournal.org/content/122/21/654 Mahon et al. 2013 (STIM2)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Imatinib (Gleevec)]] (dose not specified)

'''Treatment is discontinued if "sustained DMR defined as remission lasting more than 2 consecutive years and confirmed on five datapoints of BCR–ABL analyses by quantitative RT-PCR during these 2 years" occurs.'''

===Variant #2 {{#subobject:717a4c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.bloodjournal.org/content/122/4/515.long Ross et al. 2013 (TWISTER)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Imatinib (Gleevec)]] (dose not specified)

'''Treatment is discontinued after a minimum of 3 years of imatinib and 2 years of sustained undetectable minimal residual disease by conventional PCR.'''

===References===
# Mahon FX, Réa D, Guilhot J, Guilhot F, Huguet F, Nicolini F, Legros L, Charbonnier A, Guerci A, Varet B, Etienne G, Reiffers J, Rousselot P; Intergroupe Français des Leucémies Myéloïdes Chroniques. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010 Nov;11(11):1029-35. Epub 2010 Oct 19. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(10)70233-3/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/20965785 PubMed] 
## '''Update:''' Etienne G, Guilhot J, Rea D, Rigal-Huguet F, Nicolini F, Charbonnier A, Guerci-Bresler A, Legros L, Varet B, Gardembas M, Dubruille V, Tulliez M, Noel MP, Ianotto JC, Villemagne B, Carré M, Guilhot F, Rousselot P, Mahon FX. Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia. J Clin Oncol. 2017 Jan 20;35(3):298-305. [http://ascopubs.org/doi/full/10.1200/JCO.2016.68.2914 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28095277 PubMed]
# Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, Dang P, Goyne JM, Slader C, Filshie RJ, Mills AK, Melo JV, White DL, Grigg AP, Hughes TP. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013 Jul 25;122(4):515-22. Epub 2013 May 23. [http://www.bloodjournal.org/content/122/4/515.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23704092 PubMed]
# '''Abstract:''' Francois-Xavier Mahon, MD, PhD, Franck E. Nicolini, Marie-Pierre Noël, Martine Escoffre, Aude Charbonnier, Delphine Rea, Viviane Dubruille, Bruno R. Varet, Laurence Legros, Agnès Guerci, Gabriel Etienne, Francois Guilhot, Stéphanie Dulucq, Philippe Rousselot, Joelle Guilhot. Preliminary Report Of The STIM2 Study: A Multicenter Stop Imatinib Trial For Chronic Phase Chronic Myeloid Leukemia De Novo Patients On Imatinib. Blood Nov 2013,122(21)654 [http://www.bloodjournal.org/content/122/21/654 link to original abstract]

==Imatinib & LoDAC {{#subobject:c3eaec|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
Imatinib & LoDAC: Imatinib & '''<u>Lo</u>'''w '''<u>D</u>'''ose '''<u>A</u>'''ra-'''<u>C</u>'''

===Regimen {{#subobject:c45672|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=3|[https://www.nejm.org/doi/full/10.1056/NEJMoa1004095 Preudhomme et al. 2010 (SPIRIT)]
|rowspan=3 style="background-color:#1a9851"|Phase III (E)
|1. [[#Imatinib_monotherapy|Imatinib 400 mg daily]]
|style="background-color:#d3d3d3"|Not reported
|-
|2. Imatinib 600 mg daily
|style="background-color:#d3d3d3"|Not reported
|-
|3. [[#Imatinib_.26_Interferon_alfa-2a|Imatinib & Interferon alfa]]
|style="background-color:#d3d3d3"|Not reported
|-
|}
====Chemotherapy====
*[[Imatinib (Gleevec)]] 400 mg PO once per day
*[[Cytarabine (Cytosar)]] 20 mg/m<sup>2</sup> SC once per day on days 15 to 28

'''28-day cycles for at least 12 months or until progression'''

===References===
<!-- Presented in part at the annual meeting of the American Society of Hematology, New Orleans, December 7, 2009. -->
# '''SPIRIT:''' Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, Maloisel F, Coiteux V, Gardembas M, Berthou C, Vekhoff A, Rea D, Jourdan E, Allard C, Delmer A, Rousselot P, Legros L, Berger M, Corm S, Etienne G, Roche-Lestienne C, Eclache V, Mahon FX, Guilhot F; SPIRIT Investigators; France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC). Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med. 2010 Dec 23;363(26):2511-21. [https://www.nejm.org/doi/full/10.1056/NEJMoa1004095 link to original article] '''contains partial verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21175313 PubMed]

==Imatinib & Interferon alfa-2a {{#subobject:1ffe94|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Variant #1, peginterferon {{#subobject:a7b7be|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=3|[https://www.nejm.org/doi/full/10.1056/NEJMoa1004095 Preudhomme et al. 2010 (SPIRIT)]
|rowspan=3 style="background-color:#1a9851"|Phase III (E)
|1. [[#Imatinib_monotherapy|Imatinib 400 mg daily]]
|style="background-color:#1a9850"|Superior [[Response_to_treatment#Molecular_response|MMR rate]] at 12 months
|-
|2. Imatinib 600 mg daily
|style="background-color:#d3d3d3"|Not reported
|-
|3. [[#Imatinib_.26_LoDAC|Imatinib & LoDAC]]
|style="background-color:#d3d3d3"|Not reported
|-
|}
''Preudhomme et al. amended their protocol to reduce the dose of peginterferon; Johnson-Ansah et al. demonstrated (post-hoc) that the reduced dose was still efficacious.''
====Chemoimmunotherapy====
*[[Imatinib (Gleevec)]] 400 mg PO once per day
*[[Peginterferon alfa-2a (Pegasys)]] 45 mcg or 90 mcg SC once per week

'''Continued indefinitely'''

===Variant #2 {{#subobject:b02b8b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[http://jco.ascopubs.org/content/29/12/1634.long Hehlmann et al. 2011 (CML-Study IV)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[#Imatinib_monotherapy|Imatinib]]
|style="background-color:#d3d3d3"|Not reported
|-
|2. [[#Imatinib_monotherapy.2C_high_dose|Imatinib, high dose]]
|style="background-color:#d73027"|Inferior [[Response_to_treatment#Molecular_response|MMR rate]] at 12 months
|-
|}
====Chemoimmunotherapy====
*[[Imatinib (Gleevec)]] 400 mg PO once per day
*ONE of the following:
**[[Interferon alfa-2a (Roferon-A)]]
**[[Interferon alfa-2b (Intron-A)]] 1.5 million units SC three times per week, increased up to 3 million units SC three times per week as tolerated; starts after 6 weeks of imatinib monotherapy.

'''Continued indefinitely'''

===References===
<!-- Presented in part at the annual meeting of the American Society of Hematology, New Orleans, December 7, 2009. -->
# '''SPIRIT:''' Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, Maloisel F, Coiteux V, Gardembas M, Berthou C, Vekhoff A, Rea D, Jourdan E, Allard C, Delmer A, Rousselot P, Legros L, Berger M, Corm S, Etienne G, Roche-Lestienne C, Eclache V, Mahon FX, Guilhot F; SPIRIT Investigators; France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC). Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med. 2010 Dec 23;363(26):2511-21. [https://www.nejm.org/doi/full/10.1056/NEJMoa1004095 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21175313 PubMed]
## '''Post-hoc analysis:''' Johnson-Ansah H, Guilhot J, Rousselot P, Rea D, Legros L, Rigal-Huguet F, Nicolini FE, Mahon FX, Preudhomme C, Guilhot F. Tolerability and efficacy of pegylated interferon-a-2a in combination with imatinib for patients with chronic-phase chronic myeloid leukemia. Cancer. 2013 Dec 15;119(24):4284-9. Epub 2013 Sep 16. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.28328/full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/24105694 PubMed]
<!-- Presented in part at the 51st Annual Meeting of the American Society of Hematology, New Orleans, LA, December 5-8, 2009; at the 46th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 4-7, 2010; and at the Annual Meeting of the European Hematology Association, Barcelona, Spain, June 9-11, 2010. -->
# '''CML-Study IV:''' Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, Müller MC, Pletsch N, Proetel U, Haferlach C, Schlegelberger B, Balleisen L, Hänel M, Pfirrmann M, Krause SW, Nerl C, Pralle H, Gratwohl A, Hossfeld DK, Hasford J, Hochhaus A, Saussele S. Tolerability-adapted imatinib 800 mg/day versus 400 mg/day versus 400 mg/day plus interferon-a in newly diagnosed chronic myeloid leukemia. J Clin Oncol. 2011 Apr 20;29(12):1634-42. Epub 2011 Mar 21. [http://jco.ascopubs.org/content/29/12/1634.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21422420 PubMed] 
## '''Update:''' Hehlmann R, Müller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A, Proetel U, Pletsch N, Pfirrmann M, Haferlach C, Schnittger S, Einsele H, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Ehninger G, Heim D, Heimpel H, Nerl C, Krause SW, Hossfeld DK, Kolb HJ, Hasford J, Saußele S, Hochhaus A. Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV. J Clin Oncol. 2014 Feb 10;32(5):415-23. Epub 2013 Dec 2. [http://jco.ascopubs.org/content/32/5/415.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24297946 PubMed]
## '''Update:''' Kalmanti L, Saussele S, Lauseker M, Müller MC, Dietz CT, Heinrich L, Hanfstein B, Proetel U, Fabarius A, Krause SW, Rinaldetti S, Dengler J, Falge C, Oppliger-Leibundgut E, Burchert A, Neubauer A, Kanz L, Stegelmann F, Pfreundschuh M, Spiekermann K, Scheid C, Pfirrmann M, Hochhaus A, Hasford J, Hehlmann R. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia. 2015 May;29(5):1123-32. Epub 2015 Feb 13. [https://www.nature.com/leu/journal/v29/n5/full/leu201536a.html link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25676422 PubMed]
## '''Update:''' Hehlmann R, Lauseker M, Saußele S, Pfirrmann M, Krause S, Kolb HJ, Neubauer A, Hossfeld DK, Nerl C, Gratwohl A, Baerlocher GM, Heim D, Brümmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Müller MC, Jeromin S, Proetel U, Kohlbrenner K, Voskanyan A, Rinaldetti S, Seifarth W, Spieß B, Balleisen L, Goebeler MC, Hänel M, Ho A, Dengler J, Falge C, Kanz L, Kremers S, Burchert A, Kneba M, Stegelmann F, Köhne CA, Lindemann HW, Waller CF, Pfreundschuh M, Spiekermann K, Berdel WE, Müller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Pezzutto A, Schenk M, Brossart P, Geer T, Bildat S, Schäfer E, Hochhaus A, Hasford J. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017 Nov;31(11):2398-2406. Epub 2017 Aug 14. [https://www.nature.com/leu/journal/v31/n11/full/leu2017253a.html link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28804124 PubMed]

==Interferon alfa monotherapy {{#subobject:7d153e|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:8dab8f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM198604243141701 Talpaz et al. 1986]
| style="background-color:#91cf61" |Non-randomized
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.nejm.org/doi/10.1056/NEJM199403243301204 Tura et al. 1994]
|style="background-color:#1a9851"|Phase III (E)
|1. Busulfan<br> 2. Hydroxyurea
| style="background-color:#1a9850" |Superior OS
|-
|rowspan=2|[http://www.bloodjournal.org/content/84/12/4064.long Hehlmann et al. 1994]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. Busulfan
| style="background-color:#1a9850" |Superior OS
|-
|2. Hydroxyurea
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(95)92596-1.pdf Allan et al. 1995]
|style="background-color:#1a9851"|Phase III (E)
|1. Busulfan<br> 2. Hydroxyurea
| style="background-color:#1a9850" |Superior OS
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM199707243370402 Guilhot et al. 1997]
|style="background-color:#1a9851"|Phase III (C)
|[[#Cytarabine_.26_Interferon_alfa-2b|LoDAC & Interferon alfa]]
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|[https://www.nature.com/articles/2403217 Michallet et al. 2004]
|style="background-color:#1a9851"|Phase III (C)
|Peg-IFN
| style="background-color:#ffffbf" |Inconclusive whether non-inferior
|-
|}
''Of historical interest; many of the older trials do not specify the exact type of interferon alfa.''
====Immunotherapy====
*[[:Category:Interferons|Interferon alfa]]

'''Continued indefinitely'''
===References===
# Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Keating MJ, Gutterman JU. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med. 1986 Apr 24;314(17):1065-9. [https://www.nejm.org/doi/full/10.1056/NEJM198604243141701 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/3457264 PubMed]
# Tura S, Baccarani M, Zuffa E, Russo D, Fanin R, Zaccaria A, Fiacchini M; Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med. 1994 Mar 24;330(12):820-5. [https://www.nejm.org/doi/10.1056/NEJM199403243301204 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/8114834 PubMed]
# Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Queisser W, Löffler H, Hochhaus A, Heinze B, Georgii A, Bartram CR, Griesshammer M, Bergmann L, Essers U, Falge C, Queisser U, Meyer P, Schmitz N, Eimermacher H, Walther F, Fett W, Kleeberg UR, Kabisch A, Nerl C, Zimmermann R, Meuret G, Tichelli A, Kanz L, Tigges FJ, Schmid L, Brockhaus W, Tobler A, Reiter A, Perker M, Emmerich B, Verpoort K, Zankovich R, Wussow PV, Prummer O, Thiele J, Buhr T, Carbonell F, Ansari H; The German CML Study Group. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood. 1994 Dec 15;84(12):4064-77. [http://www.bloodjournal.org/content/84/12/4064.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/7994025 PubMed]
# Allan NC, Richards SM, Shepherd PC; The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. Lancet. 1995 Jun 3;345(8962):1392-7. [https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(95)92596-1.pdf link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/7760609 PubMed]
# Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau JL, Maloisel F, Bouabdallah R, Guyotat D, Cheron N, Nicolini F, Abgrall JF, Tanzer J; French Chronic Myeloid Leukemia Study Group. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med. 1997 Jul 24;337(4):223-9. [https://www.nejm.org/doi/full/10.1056/NEJM199707243370402 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9227927 PubMed]
# Michallet M, Maloisel F, Delain M, Hellmann A, Rosas A, Silver RT, Tendler C; PEG-Intron CML Study Group. Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study. Leukemia. 2004 Feb;18(2):309-15. [https://www.nature.com/articles/2403217 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/14671645 PubMed]

==Nilotinib monotherapy {{#subobject:379fef|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Variant #1, 300 mg twice per day {{#subobject:d315bd|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[https://www.nejm.org/doi/full/10.1056/NEJMoa0912614 Saglio et al. 2010 (ENESTnd)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[#Imatinib_monotherapy|Imatinib]]
|style="background-color:#91cf60"|Seems to have superior TTP
|-
|2. Nilotinib 400 mg twice per day
|style="background-color:#d3d3d3"|Not reported
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4416528/ Wang et al. 2015 (ENESTchina)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Imatinib_monotherapy|Imatinib]]
|style="background-color:#1a9850"|Superior [[Response_to_treatment#Molecular_response|MMR rate]] at 12 months
|-
|}

''The ENESTnd study was not powered to detect differences between the two doses of nilotinib.''
====Chemotherapy====
*[[Nilotinib (Tasigna)]] 300 mg PO twice per day

'''Continued indefinitely'''

===Variant #2, 400 mg twice per day {{#subobject:f15948|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.bloodjournal.org/content/114/24/4933.long Rosti et al. 2009]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|rowspan=2|[https://www.nejm.org/doi/full/10.1056/NEJMoa0912614 Saglio et al. 2010 (ENESTnd)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[#Imatinib_monotherapy|Imatinib]]
|style="background-color:#1a9850"|Superior TTP
|-
|2. Nilotinib 300 mg twice per day
|style="background-color:#d3d3d3"|Not reported
|-
|}
''The ENESTnd study was not powered to detect differences between the two doses of nilotinib.''
====Chemotherapy====
*[[Nilotinib (Tasigna)]] 400 mg PO twice per day

'''Continued indefinitely'''

===References===
<!--Rosti G, Castagnetti F, Poerio A, et al. High and early rates of cytogenetic and molecular response with nilotinib 800 mg daily as first line treatment of Ph-positive chronic myeloid leukemia in chronic phase: results of a phase 2 trial of the GIMEMA CML working party [abstract]. Blood 2008;112(11):73-74. Abstract 181.-->
# Rosti G, Palandri F, Castagnetti F, Breccia M, Levato L, Gugliotta G, Capucci A, Cedrone M, Fava C, Intermesoli T, Cambrin GR, Stagno F, Tiribelli M, Amabile M, Luatti S, Poerio A, Soverini S, Testoni N, Martinelli G, Alimena G, Pane F, Saglio G, Baccarani M; GIMEMA CML Working Party. Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. Blood. 2009 Dec 3;114(24):4933-8. Epub 2009 Oct 12. [http://www.bloodjournal.org/content/114/24/4933.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19822896 PubMed]
## '''Update:''' Gugliotta G, Castagnetti F, Breccia M, Levato L, D'Adda M, Stagno F, Tiribelli M, Salvucci M, Fava C, Martino B, Cedrone M, Bocchia M, Trabacchi E, Cavazzini F, Usala E, Russo Rossi A, Bochicchio MT, Soverini S, Alimena G, Cavo M, Pane F, Martinelli G, Saglio G, Baccarani M, Rosti G; GIMEMA CML Working Party. Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia. Haematologica. 2015 Sep;100(9):1146-50. Epub 2015 Jun 25. [http://www.haematologica.org/content/100/9/1146 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4800682/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26113419 PubMed]
# '''ENESTnd:''' Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM; ENESTnd Investigators. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010 Jun 17;362(24):2251-9. Epub 2010 Jun 5. [https://www.nejm.org/doi/full/10.1056/NEJMoa0912614 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20525993 PubMed]
## '''Update:''' Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, Goh YT, Rosti G, Nakamae H, Gallagher NJ, Hoenekopp A, Blakesley RE, Larson RA, Hughes TP. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011 Sep;12(9):841-51. Epub 2011 Aug 17. Erratum in: Lancet Oncol. 2011 Oct;12(11):989. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70201-7/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21856226 PubMed]
## '''Update:''' Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, Kim DW, Flinn IW, Kurokawa M, Moiraghi B, Yu R, Blakesley RE, Gallagher NJ, Saglio G, Kantarjian HM. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia. 2012 Oct;26(10):2197-203. Epub 2012 May 18. [https://www.nature.com/leu/journal/v26/n10/full/leu2012134a.html?WT.ec_id=LEU-201210 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22699418 PubMed]
<!-- ## '''Update: Abstract:''' Hughes TP, le Coutre PD, Jootar S, et al. ENESTnd 5-year follow-up: continued benefit of frontline nilotinib (NIL) compared with imatinib (IM) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) [abstract]. Haematologica. 2014. 99. Abstract s677. -->
## '''Update:''' Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre PD, Etienne G, Dorlhiac-Llacer PE, Clark RE, Flinn IW, Nakamae H, Donohue B, Deng W, Dalal D, Menssen HD, Kantarjian HM. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016 May;30(5):1044-54. Epub 2016 Feb 3. [https://www.nature.com/leu/journal/v30/n5/full/leu20165a.html link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4858585/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26837842 PubMed]
# '''ENESTchina:''' Wang J, Shen ZX, Saglio G, Jin J, Huang H, Hu Y, Du X, Li J, Meng F, Zhu H, Hu J, Wang J, Hou M, Hertle S, Menssen HD, Ortmann CE, Tribouley C, Yuan Y, Baccarani M, Huang X. Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina. Blood. 2015 Apr 30;125(18):2771-8. Epub 2015 Mar 12. [http://www.bloodjournal.org/content/125/18/2771.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4416528/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25766724 PubMed]

==Radotinib monotherapy {{#subobject:32cbb0|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 300 mg twice per day {{#subobject:c201df|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[http://clincancerres.aacrjournals.org/content/23/23/7180.long Kwak et al. 2017 (RERISE)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[#Imatinib_monotherapy|Imatinib]]
|style="background-color:#1a9850"|Superior [[Response_to_treatment#Molecular_response|MMR rate]] at 12 months
|-
|2. Radotinib 400 mg twice per day
|style="background-color:#d3d3d3"|Not reported
|-
|}
====Chemotherapy====
*[[Radotinib (Supect)]] 300 mg PO twice per day

'''Continued indefinitely'''

===Variant #2, 400 mg twice per day {{#subobject:5ab705|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.haematologica.org/content/99/7/1191.long Kim et al. 2014]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|rowspan=2|[http://clincancerres.aacrjournals.org/content/23/23/7180.long Kwak et al. 2017 (RERISE)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[#Imatinib_monotherapy|Imatinib]]
|style="background-color:#91cf60"|Seems to have superior [[Response_to_treatment#Molecular_response|MMR rate]] at 12 months
|-
|2. Radotinib 300 mg twice per day
|style="background-color:#d3d3d3"|Not reported
|-
|}
====Chemotherapy====
*[[Radotinib (Supect)]] 400 mg PO twice per day

'''Continued indefinitely'''

===References===
# Kim SH, Menon H, Jootar S, Saikia T, Kwak JY, Sohn SK, Park JS, Jeong SH, Kim HJ, Kim YK, Oh SJ, Kim H, Zang DY, Chung JS, Shin HJ, Do YR, Kim JA, Kim DY, Choi CW, Park S, Park HL, Lee GY, Cho DJ, Shin JS, Kim DW. Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors. Haematologica. 2014 Jul;99(7):1191-6. Epub 2014 Apr 4. [http://www.haematologica.org/content/99/7/1191.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4077080/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24705186 PubMed]
# Kwak JY, Kim SH, Oh SJ, Zang DY, Kim H, Kim JA, Do YR, Kim HJ, Park JS, Choi CW, Lee WS, Mun YC, Kong JH, Chung JS, Shin HJ, Kim DY, Park J, Jung CW, Bunworasate U, Comia NS, Jootar S, Reksodiputro AH, Caguioa PB, Lee SE, Kim DW. Phase III clinical trial (RERISE study) results of efficacy and safety of radotinib compared with imatinib in newly diagnosed chronic phase chronic myeloid leukemia. Clin Cancer Res. 2017 Dec 1;23(23):7180-7188. Epub 2017 Sep 22. [http://clincancerres.aacrjournals.org/content/23/23/7180.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28939746 PubMed]

=Chronic phase, relapsed or refractory=

==Bosutinib monotherapy {{#subobject:302a11|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:7a8e85|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916618/ Cortes et al. 2011 (B1871006)]
|style="background-color:#91cf61"|Phase I/II
|-
|}
''Note: the dosing described is that reported for the phase 2 portion of the phase 1/2 study. Suboptimal response defined as no [[Response_to_treatment#Hematologic_response_.28HR.29|complete hematologic response (CHR)]] by week 8 or [[Response_to_treatment#Cytogenetic_response|complete cytogenetic response (CCyR)]] by week 12.''
====Chemotherapy====
*[[Bosutinib (Bosulif)]] 500 mg PO once per day, take with food
**If no grade 3 or higher drug-related toxicity occurs, dose can be escalated to 600 mg PO once per day if response is suboptimal

'''Continued indefinitely'''

===References===
# '''B1871006:''' Cortes JE, Kantarjian HM, Brümmendorf TH, Kim DW, Turkina AG, Shen ZX, Pasquini R, Khoury HJ, Arkin S, Volkert A, Besson N, Abbas R, Wang J, Leip E, Gambacorti-Passerini C. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011 Oct 27;118(17):4567-76. Epub 2011 Aug 24. Erratum in: Blood. 2013 Oct 3;122(14):2524. [http://www.bloodjournal.org/content/118/17/4567.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916618/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21865346 PubMed]
## '''Update:''' Khoury HJ, Cortes JE, Kantarjian HM, Gambacorti-Passerini C, Baccarani M, Kim DW, Zaritskey A, Countouriotis A, Besson N, Leip E, Kelly V, Brümmendorf TH. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood. 2012 Apr 12;119(15):3403-12. Epub 2012 Feb 27. [http://www.bloodjournal.org/content/119/15/3403.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916559/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22371878 PubMed]
## '''Update:''' Kantarjian HM, Cortes JE, Kim DW, Khoury HJ, Brümmendorf TH, Porkka K, Martinelli G, Durrant S, Leip E, Kelly V, Turnbull K, Besson N, Gambacorti-Passerini C. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Blood. 2014 Feb 27;123(9):1309-18. Epub 2013 Dec 17. [http://www.bloodjournal.org/content/123/9/1309.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467890/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24345751 PubMed]
## '''Update:''' Gambacorti-Passerini C, Brümmendorf TH, Kim DW, Turkina AG, Masszi T, Assouline S, Durrant S, Kantarjian HM, Khoury HJ, Zaritskey A, Shen ZX, Jin J, Vellenga E, Pasquini R, Mathews V, Cervantes F, Besson N, Turnbull K, Leip E, Kelly V, Cortes JE. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up. Am J Hematol. 2014 Jul;89(7):732-42. Epub 2014 Apr 28. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4173127/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24711212 PubMed]
## '''Update:''' Gambacorti-Passerini C, Kantarjian HM, Kim DW, Khoury HJ, Turkina AG, Brümmendorf TH, Matczak E, Bardy-Bouxin N, Shapiro M, Turnbull K, Leip E, Cortes JE. Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors. Am J Hematol. 2015 Sep;90(9):755-68. Epub 2015 Jun 1. [https://onlinelibrary.wiley.com/doi/10.1002/ajh.24034/full link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5132035/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26040495 PubMed]

==BuCyTBI, then allo HSCT {{#subobject:44b691|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
BuCyTBI: '''<u>Bu</u>'''sulfan, '''<u>Cy</u>'''clophosphamide, '''<u>T</u>'''otal '''<u>B</u>'''ody '''<u>I</u>'''rradiation
===Regimen {{#subobject:ab84cb|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM197902153000702 Fefer et al. 1979]
| style="background-color:#ffffbe" |Pilot, <20 pts
|-
|}
{{#lst:Allogeneic HSCT|ab84cb}}
===References===
# Fefer A, Cheever MA, Thomas ED, Boyd C, Ramberg R, Glucksberg H, Buckner CD, Storb R. Disappearance of Ph1-positive cells in four patients with chronic granulocytic leukemia after chemotherapy, irradiation and marrow transplantation from an identical twin. N Engl J Med. 1979 Feb 15;300(7):333-7. [https://www.nejm.org/doi/full/10.1056/NEJM197902153000702 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/366408 PubMed]

==Busulfan monotherapy {{#subobject:24be30|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:b774ed|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM195605242542104 Schilling & Meyer 1956]
| style="background-color:#ffffbe" |Non-randomized, <20 pts
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM195704182561602 Unugur et al. 1957]
| style="background-color:#91cf61" |Non-randomized
|-
|}
''Of historic interest.''
====Chemotherapy====
*[[Busulfan (Myleran)]]
===References===
# Schilling RF, Meyer OO. Treatment of chronic granulocytic leukemia with 1, 4-dimethanesulfonyloxybutane (Myleran). N Engl J Med. 1956 May 24;254(21):986-9. [https://www.nejm.org/doi/full/10.1056/NEJM195605242542104 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/13322198 PubMed]
# Unugur A, Schulman E, Dameshek W. Treatment of chronic granulocytic leukemia with Myleran. N Engl J Med. 1957 Apr 18;256(16):727-34. [https://www.nejm.org/doi/full/10.1056/NEJM195704182561602 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/13451927 PubMed]

==Cyclophosphamide & TBI, then allo HSCT {{#subobject:a9f7e8|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
Cy/TBI: '''<u>Cy</u>'''clophosphamide & '''<u>T</u>'''otal '''<u>B</u>'''ody '''<u>I</u>'''rradiation
===Regimen {{#subobject:6ca28d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM198201143060202 Fefer et al. 1982]
| style="background-color:#ffffbe" |Non-randomized, <20 pts
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(84)92179-2/fulltext Speck et al. 1984]
| style="background-color:#91cf61" |Non-randomized
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM198601233140403 Goldman et al. 1986]
| style="background-color:#91cf61" |Non-randomized
|-
|[https://www.nejm.org/doi/10.1056/NEJM199804023381405 Hansen et al. 1998]
| style="background-color:#91cf61" |Non-randomized
|-
|}
{{#lst:Allogeneic HSCT|6ca28d}}
===References===
# Fefer A, Cheever MA, Greenberg PD, Appelbaum FR, Boyd CN, Buckner CD, Kaplan HG, Ramberg R, Sanders JE, Storb R, Thomas ED. Treatment of chronic granulocytic leukemia with chemoradiotherapy and transplantation of marrow from identical twins. N Engl J Med. 1982 Jan 14;306(2):63-8. [https://www.nejm.org/doi/full/10.1056/NEJM198201143060202 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/7031474 PubMed]
# Speck B, Bortin MM, Champlin R, Goldman JM, Herzig RH, McGlave PB, Messner HA, Weiner RS, Rimm AA. Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia. Lancet. 1984 Mar 24;1(8378):665-8. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(84)92179-2/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/6142357 PubMed]
# Goldman JM, Apperley JF, Jones L, Marcus R, Goolden AW, Batchelor R, Hale G, Waldmann H, Reid CD, Hows J, Gordon-Smith E, Catovsky D, Galton DAG. Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med. 1986 Jan 23;314(4):202-7. [https://www.ncbi.nlm.nih.gov/pubmed/3510388 PubMed]
# Hansen JA, Gooley TA, Martin PJ, Appelbaum F, Chauncey TR, Clift RA, Petersdorf EW, Radich J, Sanders JE, Storb RF, Sullivan KM, Anasetti C. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med. 1998 Apr 2;338(14):962-8. [https://www.nejm.org/doi/10.1056/NEJM199804023381405 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/9521984 PubMed]

==Dasatinib monotherapy {{#subobject:51eb88|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 70 mg twice per day {{#subobject:3f39e1|Variant=1}}=== 
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa055229 Talpaz et al. 2006 (BMS-CA180002)]
|style="background-color:#91cf61"|Phase 1, >20 pts in this dosing cohort
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[http://www.bloodjournal.org/content/109/6/2303.long Hochhaus et al. 2006]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[http://www.bloodjournal.org/content/109/12/5143.long Kantarjian et al. 2007<sub>CML</sub>]
|style="background-color:#1a9851"|Randomized Phase II (E)
|[[#Imatinib_monotherapy_2|High-dose imatinib]]
|style="background-color:#1a9850"|Superior PFS
|-
|rowspan=3|[http://jco.ascopubs.org/content/26/19/3204.long Shah et al. 2008 (CA180-034)]
|rowspan=3 style="background-color:#1a9851"|Phase III (C)
|1. Dasatinib 100 mg daily
|style="background-color:#ffffbf"|Seems not superior
|-
|2. Dasatinib 140 mg daily
|style="background-color:#ffffbf"|Seems not superior
|-
|3. Dasatinib 50 mg twice per day
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Note: this is the most common dosing used in BMS-CA180002, but was not specifically recommended as the dose for subsequent trials. The trial by Kantarjian et al. 2007 should not be confused for one with the same name in MDS/CMML.''
====Chemotherapy====
*[[Dasatinib (Sprycel)]] 70 mg PO twice per day
**Reduction to 40 mg PO twice per day or escalation to 90 mg PO twice per day allowed under certain circumstances; see original papers for details.

===Variant #2, 100 mg/day {{#subobject:c86ad6|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=3|[http://jco.ascopubs.org/content/26/19/3204.long Shah et al. 2008 (CA180-034)]
|rowspan=3 style="background-color:#1a9851"|Phase III (E)
|1. Dasatinib 140 mg daily
|style="background-color:#ffffbf"|Seems not superior
|-
|2. Dasatinib 50 mg twice per day
|style="background-color:#ffffbf"|Seems not superior
|-
|3. Dasatinib 70 mg twice per day
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Note: dose escalation is not described in the FDA-recommended dosing.''
====Chemotherapy====
*[[Dasatinib (Sprycel)]] 100 mg PO once per day
**Dose may be escalated to 140 mg PO once per day or 70 mg PO twice per day depending on response, see paper.

===References===
# '''Phase 1:''' Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP, Sawyers CL. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006 Jun 15;354(24):2531-41. [https://www.nejm.org/doi/full/10.1056/NEJMoa055229 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16775234 PubMed]
# '''Post-hoc analysis:''' Quintas-Cardama A, Kantarjian H, Jones D, Nicaise C, O'Brien S, Giles F, Talpaz M, Cortes J. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood. 2007 Jan 15;109(2):497-9. Epub 2006 Sep 21. [http://www.bloodjournal.org/content/109/2/497.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16990591 PubMed]
# Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ, Facon T, Goldberg SL, Cervantes F, Niederwieser D, Silver RT, Stone RM, Hughes TP, Muller MC, Ezzeddine R, Countouriotis AM, Shah NP. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007 Mar 15;109(6):2303-9. Epub 2006 Nov 30. Erratum in: Blood. 2007 Sep 1;110(5):1438. [http://www.bloodjournal.org/content/109/6/2303.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17138817 PubMed]
## '''Update:''' Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL, Corm S, Shah NP, Cervantes F, Silver RT, Niederwieser D, Stone RM, Dombret H, Larson RA, Roy L, Hughes T, Müller MC, Ezzeddine R, Countouriotis AM, Kantarjian HM. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 2008 Jun;22(6):1200-6. Epub 2008 Apr 10. [https://www.nature.com/leu/journal/v22/n6/full/leu200884a.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18401416 PubMed]
# Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki J, Jootar S, Robak T, Khoroshko N, Masszi T, Skotnicki A, Hellmann A, Zaritsky A, Golenkov A, Radich J, Hughes T, Countouriotis A, Shah N. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood. 2007 Jun 15;109(12):5143-50. Epub 2007 Feb 22. [http://www.bloodjournal.org/content/109/12/5143.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17317857 PubMed]
# '''CA180-034:''' Shah NP, Kantarjian HM, Kim DW, Réa D, Dorlhiac-Llacer PE, Milone JH, Vela-Ojeda J, Silver RT, Khoury HJ, Charbonnier A, Khoroshko N, Paquette RL, Deininger M, Collins RH, Otero I, Hughes T, Bleickardt E, Strauss L, Francis S, Hochhaus A. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol. 2008 Jul 1;26(19):3204-12. Epub 2008 Jun 9. [http://jco.ascopubs.org/content/26/19/3204.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18541900 PubMed]
## '''Update:''' Shah NP, Kim DW, Kantarjian H, Rousselot P, Llacer PE, Enrico A, Vela-Ojeda J, Silver RT, Khoury HJ, Müller MC, Lambert A, Matloub Y, Hochhaus A. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica. 2010 Feb;95(2):232-40. [http://www.bloodjournal.org/content/112/3/516.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2817025/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20139391 PubMed] 
## '''Update:''' Shah NP, Guilhot F, Cortes JE, Schiffer CA, le Coutre P, Brümmendorf TH, Kantarjian HM, Hochhaus A, Rousselot P, Mohamed H, Healey D, Cunningham M, Saglio G. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood. 2014 Apr 10;123(15):2317-24. Epub 2014 Feb 25. [http://www.bloodjournal.org/content/123/15/2317.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4915794/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24569263 PubMed]
## '''Update:''' Shah NP, Rousselot P, Schiffer C, Rea D, Cortes JE, Milone J, Mohamed H, Healey D, Kantarjian H, Hochhaus A, Saglio G. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. Am J Hematol. 2016 Sep;91(9):869-74. Epub 2016 Jun 20. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094534/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27192969 PubMed]

==Imatinib monotherapy {{#subobject:6cdc45|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 400 mg/day {{#subobject:b5730b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM200104053441401 Druker et al. 2001]
| style="background-color:#ffffbe" |Phase 1
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa011573 Kantarjian et al. 2002 (International STI571 CML Study Group)]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2878787/ Petzer et al. 2010 (ISTAHIT)]
|style="background-color:#1a9851"|Phase III (C)
|High-dose, then standard-dose imatinib
|style="background-color:#d73027"|Inferior [[Response_to_treatment#Molecular_response|MMR rate]] at 6 months
|-
|[http://www.bloodjournal.org/content/124/5/729.long Hughes et al. 2014 (ENESTcmr)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Nilotinib_monotherapy_2|Nilotinib]]
|style="background-color:#d73027"|Inferior [[Response_to_treatment#Molecular_response|MMR rate]] at 24 months
|-
|}
''Note: patients in ENESTcmr in this arm were already taking this dose of imatinib prior to randomization.''
====Preceding treatment====
*ENESTcmr: [[#Imatinib_monotherapy|Imatinib]] for at least 2 years, with detectable BCR-ABL1
====Chemotherapy====
*[[Imatinib (Gleevec)]] 400 mg PO once per day

'''Continued indefinitely'''

===Variant #2, 600 mg/day {{#subobject:b0eb46|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.bloodjournal.org/content/124/5/729.long Hughes et al. 2014 (ENESTcmr)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Nilotinib_monotherapy_2|Nilotinib]]
|style="background-color:#d73027"|Inferior [[Response_to_treatment#Molecular_response|MMR rate]] at 24 months
|-
|[https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30167-3/fulltext Cortes et al. 2016 (LASOR)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Nilotinib_monotherapy_2|Nilotinib]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Note: patients in ENESTcmr in this arm were already taking this dose of imatinib prior to randomization.''
====Preceding treatment====
*ENESTcmr: [[#Imatinib_monotherapy|Imatinib]] for at least 2 years, with detectable BCR-ABL1
*LASOR: [[#Imatinib_monotherapy|Standard-dose imatinib]], with suboptimal response
====Chemotherapy====
*[[Imatinib (Gleevec)]] 600 mg PO once per day

'''Continued indefinitely'''

===Variant #3, 800 mg/day {{#subobject:b39310|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.bloodjournal.org/content/109/12/5143.long Kantarjian et al. 2007<sub>CML</sub>]
|style="background-color:#1a9851"|Randomized Phase II (E)
|[[#Dasatinib_monotherapy_2|Dasatinib]]
|style="background-color:#d73027"|Inferior PFS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5161008/ Yeung et al. 2014 (TIDEL-II)]
|style="background-color:#91cf61"|Non-randomized
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|}
''Note: The trial by Kantarjian et al. 2007 should not be confused for one with the same name in MDS/CMML.''
====Preceding treatment====
*TIDEL-II: [[#Imatinib_monotherapy|Imatinib 600 mg once per day]]
====Chemotherapy====
*[[Imatinib (Gleevec)]] 400 mg PO twice per day

'''Continued indefinitely'''
====Subsequent treatment====
*TIDEL-II: Patients were switched to [[#Nilotinib_monotherapy_2|nilotinib]] 3 months later if they were still failing to meet targets (see paper for details)

===Variant #4, high-dose, then standard-dose {{#subobject:dc3d36|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2878787/ Petzer et al. 2010 (ISTAHIT)]
|style="background-color:#1a9851"|Phase III (E)
|Standard-dose imatinib
|style="background-color:#1a9850"|Superior [[Response_to_treatment#Molecular_response|MMR rate]] at 6 months
|-
|}
====Chemotherapy====
*[[Imatinib (Gleevec)]] 800 mg PO once per day for 6 months, then 400 mg PO once per day

'''Continued indefinitely'''

===References===
# '''Phase I:''' Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001 Apr 5;344(14):1031-7. [https://www.nejm.org/doi/full/10.1056/NEJM200104053441401 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11287972 PubMed]
# '''International STI571 CML Study Group:''' Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B, Goldman J, O'Brien SG, Russell N, Fischer T, Ottmann O, Cony-Makhoul P, Facon T, Stone R, Miller C, Tallman M, Brown R, Schuster M, Loughran T, Gratwohl A, Mandelli F, Saglio G, Lazzarino M, Russo D, Baccarani M, Morra E; International STI571 CML Study Group. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002 Feb 28;346(9):645-52. [https://www.nejm.org/doi/full/10.1056/NEJMoa011573 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11870241 PubMed]
## '''Update:''' Hochhaus A, Druker B, Sawyers C, Guilhot F, Schiffer CA, Cortes J, Niederwieser DW, Gambacorti-Passerini C, Stone RM, Goldman J, Fischer T, O'Brien SG, Reiffers JJ, Mone M, Krahnke T, Talpaz M, Kantarjian HM. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood. 2008 Feb 1;111(3):1039-43. Epub 2007 Oct 11. [http://www.bloodjournal.org/content/111/3/1039.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17932248 PubMed]
# Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki J, Jootar S, Robak T, Khoroshko N, Masszi T, Skotnicki A, Hellmann A, Zaritsky A, Golenkov A, Radich J, Hughes T, Countouriotis A, Shah N. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood. 2007 Jun 15;109(12):5143-50. Epub 2007 Feb 22. [http://www.bloodjournal.org/content/109/12/5143.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17317857 PubMed]
# '''Case series:''' Palandri F, Iacobucci I, Martinelli G, Amabile M, Poerio A, Testoni N, Soverini S, Castagnetti F, De Vivo A, Breccia M, Specchia G, Abruzzese E, Martino B, Cilloni D, Saglio G, Pane F, Liberati AM, Rosti G, Baccarani M; GIMEMA Working Party on CML. Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. J Clin Oncol. 2008 Jan 1;26(1):106-11. [http://jco.ascopubs.org/content/26/1/106.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18165644 PubMed]
# '''ISTAHIT:''' Petzer AL, Wolf D, Fong D, Lion T, Dyagil I, Masliak Z, Bogdanovic A, Griskevicius L, Lejniece S, Goranov S, Gercheva L, Stojanovic A, Peytchev D, Tzvetkov N, Griniute R, Oucheva R, Ulmer H, Kwakkelstein M, Rancati F, Gastl G. High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study. Haematologica. 2010 Jun;95(6):908-13. Epub 2010 Feb 9. [http://www.haematologica.org/content/95/6/908.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2878787/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20145273 PubMed]
## '''Update:''' Petzer AL, Fong D, Lion T, Dyagil I, Masliak Z, Bogdanovic A, Griskevicius L, Lejniece S, Goranov S, Gercheva L, Stojanovic A, Peytchev D, Tzvetkov N, Griniute R, Stanchev A, Grubinger T, Kwakkelstein M, Schuld P, Gastl G, Wolf D. High-dose imatinib induction followed by standard-dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients--final analysis of a randomized, multicenter, phase III trial. Haematologica. 2012 Oct;97(10):1562-9. Epub 2012 Apr 17. [http://www.haematologica.org/content/97/10/1562.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3487557/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22511495 PubMed]
# '''ENESTcmr:''' Hughes TP, Lipton JH, Spector N, Cervantes F, Pasquini R, Clementino NC, Dorlhiac Llacer PE, Schwarer AP, Mahon FX, Rea D, Branford S, Purkayastha D, Collins L, Szczudlo T, Leber B. Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib. Blood. 2014 Jul 31;124(5):729-36. Epub 2014 Jun 19. [http://www.bloodjournal.org/content/124/5/729.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24948656/ PubMed]
## '''Update:''' Hughes TP, Leber B, Cervantes F, Spector N, Pasquini R, Clementino NCD, Schwarer AP, Dorlhiac-Llacer PE, Mahon FX, Rea D, Guerci-Bresler A, Kamel-Reid S, Bendit I, Acharya S, Glynos T, Dalal D, Branford S, Lipton JH. Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results. Leukemia. 2017 Nov;31(11):2529-2531. Epub 2017 Aug 3. [https://www.nature.com/articles/leu2017247 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668492/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/28862704 PubMed]
<!-- Presented in part at the 52nd annual meeting of the American Society of Hematology (ASH), Orlando, FL, December 4-7, 2010; 53rd annual meeting of the ASH, San Diego CA, December 10-13, 2011; and the 54th annual meeting of the ASH, Atlanta, GA, December 8-11, 2012. Also presented at the 16th Congress of the European Hematology Association (EHA), London, United Kingdom, June 9-12, 2011. -->
# '''TIDEL-II:''' Yeung DT, Osborn MP, White DL, Branford S, Braley J, Herschtal A, Kornhauser M, Issa S, Hiwase DK, Hertzberg M, Schwarer AP, Filshie R, Arthur CK, Kwan YL, Trotman J, Forsyth CJ, Taper J, Ross DM, Beresford J, Tam C, Mills AK, Grigg AP, Hughes TP; Australasian Leukaemia and Lymphoma Group. TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. Blood. 2015 Feb 5;125(6):915-23. Epub 2014 Dec 17. [http://www.bloodjournal.org/content/125/6/915.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5161008/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25519749 PubMed]
# '''LASOR:''' Cortes JE, De Souza CA, Ayala M, Lopez JL, Bullorsky E, Shah S, Huang X, Babu KG, Abdulkadyrov K, de Oliveira JS, Shen ZX, Sacha T, Bendit I, Liang Z, Owugah T, Szczudlo T, Khanna S, Fellague-Chebra R, le Coutre PD. Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial. Lancet Haematol. 2016 Dec;3(12):e581-e591. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30167-3/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27890073 PubMed]

==Interferon alfa-2b & DLI {{#subobject:5e6fed|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
DLI: '''<u>D</u>'''onor '''<u>L</u>'''ymphocyte '''<u>I</u>'''nfusion
===Regimen {{#subobject:26844e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.nejm.org/doi/10.1056/NEJM199401133300204 Porter et al. 1994]
| style="background-color:#ffffbe" |Non-randomized, <20 pts
|-
|}
''Of historic interest; patients had relapsed after allogeneic HSCT''
====Immunotherapy====
*[[Interferon alfa-2b (Intron-A)]]
*DLI
===References===
# Porter DL, Roth MS, McGarigle C, Ferrara JL, Antin JH. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med. 1994 Jan 13;330(2):100-6. [https://www.nejm.org/doi/10.1056/NEJM199401133300204 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/8259165 PubMed]

==Nilotinib monotherapy {{#subobject:266817|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:49d7c6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa055104 Kantarjian et al. 2006 (A2101)]
|style="background-color:#91cf61"|Phase I/II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4077082/ Hughes et al. 2014a (ENESTnd extension)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[http://www.bloodjournal.org/content/124/5/729.long Hughes et al. 2014b (ENESTcmr)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Imatinib_monotherapy_2|Imatinib]]
|style="background-color:#1a9850" |Superior [[Response_to_treatment#Molecular_response|MMR rate]] at 24 months
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5161008/ Yeung et al. 2014 (TIDEL-II)]
|style="background-color:#91cf61"|Non-randomized
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30167-3/fulltext Cortes et al. 2016 (LASOR)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Imatinib_monotherapy_2|Imatinib 600 mg daily]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Preceding treatment====
*ENESTnd extension: [[#Imatinib_monotherapy|Imatinib 400 mg once or twice per day]] or [[#Nilotinib_monotherapy|nilotinib 300 mg twice per day]], with suboptimal response/treatment failure
*ENESTcmr: [[#Imatinib_monotherapy|Imatinib]] for at least 2 years, with detectable BCR-ABL1
*TIDEL-II: [[#Imatinib_monotherapy|Imatinib]], with failure to meet molecular targets
*LASOR: [[#Imatinib_monotherapy|Standard-dose imatinib]], with suboptimal response

====Chemotherapy====
*[[Nilotinib (Tasigna)]] 400 mg PO twice per day

===References===
# '''A2101:''' Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, Bochinski K, Hochhaus A, Griffin JD, Hoelzer D, Albitar M, Dugan M, Cortes J, Alland L, Ottmann OG. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006 Jun 15;354(24):2542-51. [https://www.nejm.org/doi/full/10.1056/NEJMoa055104 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16775235 PubMed]
## '''Update:''' Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, Ossenkoppele GJ, Nicolini FE, O'Brien SG, Litzow M, Bhatia R, Cervantes F, Haque A, Shou Y, Resta DJ, Weitzman A, Hochhaus A, le Coutre P. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007 Nov 15;110(10):3540-6. Epub 2007 Aug 22. [http://www.bloodjournal.org/content/110/10/3540.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17715389 PubMed]
## '''Update:''' Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Kim DW, Shou Y, Gallagher NJ, Blakesley R, Baccarani M, Cortes J, le Coutre PD. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011 Jan 27;117(4):1141-5. Epub 2010 Nov 22. [http://www.bloodjournal.org/content/117/4/1141.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916554/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21098399 PubMed]
## '''Update:''' Giles FJ, le Coutre PD, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Kim DW, Novick S, Gillis K, Fan X, Cortes J, Baccarani M, Kantarjian HM. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia. 2013 Jan;27(1):107-12. Epub 2012 Jul 5. [https://www.nature.com/leu/journal/v27/n1/full/leu2012181a.html link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22763385 PubMed]
# '''ENESTnd extension:''' Hughes TP, Hochhaus A, Kantarjian HM, Cervantes F, Guilhot F, Niederwieser D, le Coutre PD, Rosti G, Ossenkoppele G, Lobo C, Shibayama H, Fan X, Menssen HD, Kemp C, Larson RA, Saglio G. Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily. Haematologica. 2014 Jul;99(7):1204-11. Epub 2014 Feb 14. [http://www.haematologica.org/content/99/7/1204.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4077082/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24532039 PubMed]
# '''ENESTcmr:''' Hughes TP, Lipton JH, Spector N, Cervantes F, Pasquini R, Clementino NC, Dorlhiac Llacer PE, Schwarer AP, Mahon FX, Rea D, Branford S, Purkayastha D, Collins L, Szczudlo T, Leber B. Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib. Blood. 2014 Jul 31;124(5):729-36. Epub 2014 Jun 19. [http://www.bloodjournal.org/content/124/5/729.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24948656/ PubMed]
## '''Update:''' Hughes TP, Leber B, Cervantes F, Spector N, Pasquini R, Clementino NCD, Schwarer AP, Dorlhiac-Llacer PE, Mahon FX, Rea D, Guerci-Bresler A, Kamel-Reid S, Bendit I, Acharya S, Glynos T, Dalal D, Branford S, Lipton JH. Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results. Leukemia. 2017 Nov;31(11):2529-2531. Epub 2017 Aug 3. [https://www.nature.com/articles/leu2017247 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668492/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/28862704 PubMed]
<!-- Presented in part at the 52nd annual meeting of the American Society of Hematology (ASH), Orlando, FL, December 4-7, 2010; 53rd annual meeting of the ASH, San Diego CA, December 10-13, 2011; and the 54th annual meeting of the ASH, Atlanta, GA, December 8-11, 2012. Also presented at the 16th Congress of the European Hematology Association (EHA), London, United Kingdom, June 9-12, 2011. -->
# '''TIDEL-II:''' Yeung DT, Osborn MP, White DL, Branford S, Braley J, Herschtal A, Kornhauser M, Issa S, Hiwase DK, Hertzberg M, Schwarer AP, Filshie R, Arthur CK, Kwan YL, Trotman J, Forsyth CJ, Taper J, Ross DM, Beresford J, Tam C, Mills AK, Grigg AP, Hughes TP; Australasian Leukaemia and Lymphoma Group. TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. Blood. 2015 Feb 5;125(6):915-23. Epub 2014 Dec 17. [http://www.bloodjournal.org/content/125/6/915.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5161008/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25519749 PubMed]
# '''LASOR:''' Cortes JE, De Souza CA, Ayala M, Lopez JL, Bullorsky E, Shah S, Huang X, Babu KG, Abdulkadyrov K, de Oliveira JS, Shen ZX, Sacha T, Bendit I, Liang Z, Owugah T, Szczudlo T, Khanna S, Fellague-Chebra R, le Coutre PD. Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial. Lancet Haematol. 2016 Dec;3(12):e581-e591. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30167-3/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27890073 PubMed]

==Omacetaxine monotherapy {{#subobject:fb80ac|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:e38c86|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916583/ Cortes et al. 2012 (Omacetaxine 202 Study Group)]
|style="background-color:#91cf61"|Phase II
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/ajh.23408/full Cortes et al. 2013 (Omacetaxine 203 Study Group)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy, induction phase====
*[[Omacetaxine (Synribo)]] 1.25 mg/m<sup>2</sup> SC twice per day on days 1 to 14

'''28-day cycles, given until [[Response_to_treatment#Hematologic_response_.28HR.29|hematologic response]] is achieved, followed by:'''

====Chemotherapy, maintenance phase====
*[[Omacetaxine (Synribo)]] 1.25 mg/m<sup>2</sup> SC twice per day on days 1 to 7

====Supportive medications====
*Granulocyte colony stimulating factor (G-CSF) only allowed if febrile neutropenia occurred.
*Erythropoietin/[[Epoetin alfa (Procrit)]], [[Darbepoetin alfa (Aranesp)]], or blood transfusions were allowed at any time for management of any grade of anemia.

'''28-day cycles'''

===References===
# Cortes J, Lipton JH, Rea D, Digumarti R, Chuah C, Nanda N, Benichou AC, Craig AR, Michallet M, Nicolini FE, Kantarjian H; on behalf of the Omacetaxine 202 Study Group. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood. 2012 Sep 27;120(13):2573-2580. Epub 2012 Aug 15. [http://www.bloodjournal.org/content/120/13/2573.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916583/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22896000 PubMed]
## '''Pooled subgroup analysis:''' Nicolini FE, Khoury HJ, Akard L, Rea D, Kantarjian H, Baccarani M, Leonoudakis J, Craig A, Benichou AC, Cortes J. Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors. Haematologica. 2013 Jul;98(7):e78-9. Epub 2013 Jun 10. [http://www.haematologica.org/content/98/7/e78.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3696599/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23753022 PubMed]
## '''Pooled update:''' Cortes JE, Kantarjian HM, Rea D, Wetzler M, Lipton JH, Akard L, Khoury HJ, Michallet M, Guerci-Bresler A, Chuah C, Hellmann A, Digumarti R, Parikh PM, Legros L, Warzocha K, Baccarani M, Li E, Munteanu M, Nicolini FE. Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic-or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up. Cancer. 2015 May 15;121(10):1637-44. Epub 2015 Jan 13. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.29240/full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25586015 PubMed]
<!-- # '''Abstract:''' Franck E. Nicolini, Jeffrey Howard Lipton, Hagop Kantarjian, Meir Wetzler, Luke Paul Akard, Michele Baccarani, Adam Craig, Nisha Nanda, Peter D. Brown, Jorge E. Cortes. Subcutaneous omacetaxine mepesuccinate in patients with chronic phase (CP) or accelerated phase (AP) chronic myeloid leukemia (CML) resistant/intolerant to two or three approved tyrosine-kinase inhibitors (TKIs). 2012 ASCO Annual Meeting Abstract 6513. [http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=100567 link to abstract] -->
# Cortes J, Digumarti R, Parikh PM, Wetzler M, Lipton JH, Hochhaus A, Craig AR, Benichou AC, Nicolini FE, Kantarjian HM; Omacetaxine 203 Study Group. Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors. Am J Hematol. 2013 May;88(5):350-4. Epub 2013 Mar 7. [https://onlinelibrary.wiley.com/doi/10.1002/ajh.23408/full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23468307 PubMed]
## '''Pooled subgroup analysis:''' Nicolini FE, Khoury HJ, Akard L, Rea D, Kantarjian H, Baccarani M, Leonoudakis J, Craig A, Benichou AC, Cortes J. Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors. Haematologica. 2013 Jul;98(7):e78-9. Epub 2013 Jun 10. [http://www.haematologica.org/content/98/7/e78.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3696599/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23753022 PubMed]
## '''Pooled update:''' Cortes JE, Kantarjian HM, Rea D, Wetzler M, Lipton JH, Akard L, Khoury HJ, Michallet M, Guerci-Bresler A, Chuah C, Hellmann A, Digumarti R, Parikh PM, Legros L, Warzocha K, Baccarani M, Li E, Munteanu M, Nicolini FE. Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic-or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up. Cancer. 2015 May 15;121(10):1637-44. Epub 2015 Jan 13. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.29240/full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25586015 PubMed]

==Ponatinib monotherapy {{#subobject:266235|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:9ccc94|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3777383/ Cortes et al. 2012 (AP24534-07-101)]
|style="background-color:#91cf61"|Phase 1, >20 pts
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3886799/ Cortes et al. 2013 (PACE)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Ponatinib (Iclusig)]] 45 mg PO once per day; may be taken either with or without food

'''Continued indefinitely'''

===References===
# '''Phase 1:''' Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, O'Hare T, Hu S, Narasimhan NI, Rivera VM, Clackson T, Turner CD, Haluska FG, Druker BJ, Deininger MW, Talpaz M. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012 Nov 29;367(22):2075-88. [https://www.nejm.org/doi/full/10.1056/NEJMoa1205127 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3777383/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23190221 PubMed]
# '''PACE:''' Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Goldman JM, Shah NP, Kantarjian H; the PACE Investigators. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013 Nov 7;369(19):1783-96. Epub 2013 Nov 1. [https://www.nejm.org/doi/full/10.1056/NEJMoa1306494 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3886799/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24180494 PubMed]
<!-- ## '''Update:''' '''Abstract:''' Dong-Wook Kim, Javier Pinilla-Ibarz, Philipp D le Coutre, Ronald Paquette, Charles Chuah, Franck E. Nicolini, Jane F Apperley, H. Jean Khoury, Moshe Talpaz, John F. DiPersio, Daniel J DeAngelo, Elisabetta Abruzzese, Delphine Rea, Michele Baccarani, Martin C. Müller, Carlo Gambacorti-Passerini, Stephanie Lustgarten, Victor M. Rivera, Tim Clackson, Christopher D Turner, Frank G Haluska, François Guilhot, Michael W. Deininger, Andreas Hochhaus, Timothy P. Hughes, John M Goldman, Neil P. Shah, Hagop M. Kantarjian. Ponatinib In Patients (pts) With Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Resistant Or Intolerant To Dasatinib Or Nilotinib, Or With The T315I BCR-ABL Mutation: 2-Year Follow-Up Of The PACE Trial. Blood Nov 2013,122(21)650 [http://www.bloodjournal.org/content/122/21/650 link to original abstract] -->
## '''Update:''' Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Lustgarten S, Rivera VM, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes TP, Shah NP, Kantarjian HM. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018 Jul 26;132(4):393-404. Epub 2018 Mar 22. [http://www.bloodjournal.org/content/132/4/393.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6071555/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/29567798 PubMed]

=Accelerated phase, first-line therapy=
==Imatinib monotherapy {{#subobject:2abe47|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:aed087|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.nature.com/leu/journal/v26/n10/full/leu201292a.html Rea et al. 2012]
|style="background-color:#ffffbe"|Retrospective
|-
|}
''Details of the regimen were not discernible from the manuscript. This is the FDA-recommended dose.''
====Chemotherapy====
*[[Imatinib (Gleevec)]] 600 mg PO once per day

'''Continued indefinitely'''

===References===
# '''Retrospective:''' Rea D, Etienne G, Nicolini F, Cony-Makhoul P, Johnson-Ansah H, Legros L, Huguet F, Tulliez M, Gardembas M, Bouabdallah K, Rousselot P, Cayuela JM, Guilhot F, Mahon FX. First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia. Leukemia. 2012 Oct;26(10):2254-9. Epub 2012 Mar 30. [https://www.nature.com/leu/journal/v26/n10/full/leu201292a.html link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22460758 PubMed]

=Accelerated phase, previously treated=

==Dasatinib monotherapy {{#subobject:a47c6c|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Variant #1, 70 mg twice per day {{#subobject:aa879b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.bloodjournal.org/content/109/10/4143.long Guilhot et al. 2007]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916944/ Kantarjian et al. 2009 (CA180-035)]
|style="background-color:#1a9851"|Phase III (C)
|Dasatinib 140 mg daily
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Dasatinib (Sprycel)]] 70 mg PO twice per day

===Variant #2, 140 mg/day {{#subobject:b3e556|Variant=1}}=== 
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916944/ Kantarjian et al. 2009 (CA180-035)]
|style="background-color:#1a9851"|Phase III (E)
|Dasatinib 70 mg twice per day
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Dasatinib (Sprycel)]] 140 mg PO once per day

===References===
# Guilhot F, Apperley J, Kim DW, Bullorsky EO, Baccarani M, Roboz GJ, Amadori S, de Souza CA, Lipton JH, Hochhaus A, Heim D, Larson RA, Branford S, Muller MC, Agarwal P, Gollerkeri A, Talpaz M. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood. 2007 May 15;109(10):4143-50. Epub 2007 Jan 30. [http://www.bloodjournal.org/content/109/10/4143.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17264298 PubMed]
# '''CA180-035:''' Kantarjian H, Cortes J, Kim DW, Dorlhiac-Llacer P, Pasquini R, DiPersio J, Müller MC, Radich JP, Khoury HJ, Khoroshko N, Bradley-Garelik MB, Zhu C, Tallman MS. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood. 2009 Jun 18;113(25):6322-9. Epub 2009 Apr 15. [http://www.bloodjournal.org/content/113/25/6322.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916944/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/19369231 PubMed]
## '''Subgroup analysis:''' Lilly MB, Ottmann OG, Shah NP, Larson RA, Reiffers JJ, Ehninger G, Müller MC, Charbonnier A, Bullorsky E, Dombret H, Brigid Bradley-Garelik M, Zhu C, Martinelli G. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: results from a phase 3 study. Am J Hematol. 2010 Mar;85(3):164-70. [https://onlinelibrary.wiley.com/doi/10.1002/ajh.21615/pdf link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20131302 PubMed]
## '''Subgroup analysis:''' Saglio G, Hochhaus A, Goh YT, Masszi T, Pasquini R, Maloisel F, Erben P, Cortes J, Paquette R, Bradley-Garelik MB, Zhu C, Dombret H. Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. Cancer. 2010 Aug 15;116(16):3852-61. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.25123/full link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993589/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20564086 PubMed]

==Nilotinib monotherapy {{#subobject:ca0bef|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:b1e13e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3078756/ Giles et al. 2010]
|style="background-color:#91cf61"|Phase II
|-
|[https://www.tandfonline.com/doi/full/10.3109/10428194.2011.627480 Nicolini et al. 2011 (ENACT)]
|style="background-color:#91cf61"|Phase IIIb
|-
|}
====Chemotherapy====
*[[Nilotinib (Tasigna)]] 400 mg PO twice per day

===References===
# Giles FJ, Abruzzese E, Rosti G, Kim DW, Bhatia R, Bosly A, Goldberg S, Kam GL, Jagasia M, Mendrek W, Fischer T, Facon T, Dünzinger U, Marin D, Mueller MC, Shou Y, Gallagher NJ, Larson RA, Mahon FX, Baccarani M, Cortes J, Kantarjian HM. Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia. 2010 Jul;24(7):1299-301. Epub 2010 Jun 3. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3078756/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20520639 PubMed]
## '''Update:''' le Coutre PD, Giles FJ, Hochhaus A, Apperley JF, Ossenkoppele GJ, Blakesley R, Shou Y, Gallagher NJ, Baccarani M, Cortes J, Kantarjian HM. Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. Leukemia. 2012 Jun;26(6):1189-94. Epub 2011 Nov 11. [https://www.nature.com/leu/journal/vaop/ncurrent/full/leu2011323a.html link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22076466 PubMed]
# Nicolini FE, Masszi T, Shen Z, Gallagher NJ, Jootar S, Powell BL, Dorlhiac-Llacer PE, Zheng M, Szczudlo T, Turkina A. Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis. Leuk Lymphoma. 2012 May;53(5):907-14. Epub 2011 Dec 5. [https://www.tandfonline.com/doi/full/10.3109/10428194.2011.627480 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22023530 PubMed]

==Omacetaxine monotherapy==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:e35c86|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916583/ Cortes et al. 2012 (Omacetaxine 202 Study Group)]
|style="background-color:#91cf61"|Phase II
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/ajh.23408/full Cortes et al. 2013 (Omacetaxine 203 Study Group)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy, induction phase====
*[[Omacetaxine (Synribo)]] 1.25 mg/m<sup>2</sup> SC twice per day on days 1 to 14

'''28-day cycles, given until [[Response_to_treatment#Hematologic_response_.28HR.29|hematologic response]] is achieved, followed by:'''

====Chemotherapy, maintenance phase====
*[[Omacetaxine (Synribo)]] 1.25 mg/m<sup>2</sup> SC twice per day on days 1 to 7

====Supportive medications====
*Granulocyte colony stimulating factor (G-CSF) only allowed if febrile neutropenia occurred.
*Erythropoietin/[[Epoetin alfa (Procrit)]], [[Darbepoetin alfa (Aranesp)]], or blood transfusions were allowed at any time for management of any grade of anemia.

'''28-day cycles'''

===References===
# Cortes J, Lipton JH, Rea D, Digumarti R, Chuah C, Nanda N, Benichou AC, Craig AR, Michallet M, Nicolini FE, Kantarjian H; on behalf of the Omacetaxine 202 Study Group. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood. 2012 Sep 27;120(13):2573-2580. Epub 2012 Aug 15. [http://www.bloodjournal.org/content/120/13/2573.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916583/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22896000 PubMed]
## '''Pooled subgroup analysis:''' Nicolini FE, Khoury HJ, Akard L, Rea D, Kantarjian H, Baccarani M, Leonoudakis J, Craig A, Benichou AC, Cortes J. Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors. Haematologica. 2013 Jul;98(7):e78-9. Epub 2013 Jun 10. [http://www.haematologica.org/content/98/7/e78.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3696599/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23753022 PubMed]
## '''Pooled update:''' Cortes JE, Kantarjian HM, Rea D, Wetzler M, Lipton JH, Akard L, Khoury HJ, Michallet M, Guerci-Bresler A, Chuah C, Hellmann A, Digumarti R, Parikh PM, Legros L, Warzocha K, Baccarani M, Li E, Munteanu M, Nicolini FE. Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic-or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up. Cancer. 2015 May 15;121(10):1637-44. Epub 2015 Jan 13. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.29240/full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25586015 PubMed]
<!-- # '''Abstract:''' Franck E. Nicolini, Jeffrey Howard Lipton, Hagop Kantarjian, Meir Wetzler, Luke Paul Akard, Michele Baccarani, Adam Craig, Nisha Nanda, Peter D. Brown, Jorge E. Cortes. Subcutaneous omacetaxine mepesuccinate in patients with chronic phase (CP) or accelerated phase (AP) chronic myeloid leukemia (CML) resistant/intolerant to two or three approved tyrosine-kinase inhibitors (TKIs). 2012 ASCO Annual Meeting Abstract 6513. [http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=100567 link to abstract] -->
# Cortes J, Digumarti R, Parikh PM, Wetzler M, Lipton JH, Hochhaus A, Craig AR, Benichou AC, Nicolini FE, Kantarjian HM; Omacetaxine 203 Study Group. Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors. Am J Hematol. 2013 May;88(5):350-4. Epub 2013 Mar 7. [https://onlinelibrary.wiley.com/doi/10.1002/ajh.23408/full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23468307 PubMed]
## '''Pooled subgroup analysis:''' Nicolini FE, Khoury HJ, Akard L, Rea D, Kantarjian H, Baccarani M, Leonoudakis J, Craig A, Benichou AC, Cortes J. Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors. Haematologica. 2013 Jul;98(7):e78-9. Epub 2013 Jun 10. [http://www.haematologica.org/content/98/7/e78.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3696599/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23753022 PubMed]
## '''Pooled update:''' Cortes JE, Kantarjian HM, Rea D, Wetzler M, Lipton JH, Akard L, Khoury HJ, Michallet M, Guerci-Bresler A, Chuah C, Hellmann A, Digumarti R, Parikh PM, Legros L, Warzocha K, Baccarani M, Li E, Munteanu M, Nicolini FE. Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic-or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up. Cancer. 2015 May 15;121(10):1637-44. Epub 2015 Jan 13. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.29240/full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25586015 PubMed]

==Ponatinib monotherapy {{#subobject:26a235|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:9abc94|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3777383/ Cortes et al. 2012 (AP24534-07-101)]
|style="background-color:#91cf61"|Phase 1, >20 pts
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3886799/ Cortes et al. 2013 (PACE)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Ponatinib (Iclusig)]] 45 mg PO once per day; may be taken either with or without food

'''Continued indefinitely'''

===References===
# '''Phase 1:''' Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, O'Hare T, Hu S, Narasimhan NI, Rivera VM, Clackson T, Turner CD, Haluska FG, Druker BJ, Deininger MW, Talpaz M. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012 Nov 29;367(22):2075-88. [https://www.nejm.org/doi/full/10.1056/NEJMoa1205127 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3777383/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23190221 PubMed]
# '''PACE:''' Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Goldman JM, Shah NP, Kantarjian H; the PACE Investigators. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013 Nov 7;369(19):1783-96. Epub 2013 Nov 1. [https://www.nejm.org/doi/full/10.1056/NEJMoa1306494 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3886799/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24180494 PubMed]
<!-- ## '''Update:''' '''Abstract:''' Dong-Wook Kim, Javier Pinilla-Ibarz, Philipp D le Coutre, Ronald Paquette, Charles Chuah, Franck E. Nicolini, Jane F Apperley, H. Jean Khoury, Moshe Talpaz, John F. DiPersio, Daniel J DeAngelo, Elisabetta Abruzzese, Delphine Rea, Michele Baccarani, Martin C. Müller, Carlo Gambacorti-Passerini, Stephanie Lustgarten, Victor M. Rivera, Tim Clackson, Christopher D Turner, Frank G Haluska, François Guilhot, Michael W. Deininger, Andreas Hochhaus, Timothy P. Hughes, John M Goldman, Neil P. Shah, Hagop M. Kantarjian. Ponatinib In Patients (pts) With Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Resistant Or Intolerant To Dasatinib Or Nilotinib, Or With The T315I BCR-ABL Mutation: 2-Year Follow-Up Of The PACE Trial. Blood Nov 2013,122(21)650 [http://www.bloodjournal.org/content/122/21/650 link to original abstract] -->
## '''Update:''' Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Lustgarten S, Rivera VM, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes TP, Shah NP, Kantarjian HM. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018 Jul 26;132(4):393-404. Epub 2018 Mar 22. [http://www.bloodjournal.org/content/132/4/393.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6071555/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/29567798 PubMed]

=Blast crisis=

==Bosutinib monotherapy {{#subobject:a710a8|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:39cf0d|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916618/ Cortes et al. 2011 (B1871006)]
|style="background-color:#91cf61"|Phase I/II
|-
|}
''Note: the dosing described is that reported for the phase 2 portion of the phase 1/2 study. Suboptimal response defined as no [[Response_to_treatment#Hematologic_response_.28HR.29|complete hematologic response (CHR)]] by week 8 or [[Response_to_treatment#Cytogenetic_response|complete cytogenetic response (CCyR)]] by week 12.''
====Chemotherapy====
*[[Bosutinib (Bosulif)]] 500 mg PO once per day, take with food
**If no grade 3 or higher drug-related toxicity occurs, dose can be escalated to 600 mg PO once per day if response is suboptimal

'''Continued indefinitely'''

===References===
# '''B1871006:''' Cortes JE, Kantarjian HM, Brümmendorf TH, Kim DW, Turkina AG, Shen ZX, Pasquini R, Khoury HJ, Arkin S, Volkert A, Besson N, Abbas R, Wang J, Leip E, Gambacorti-Passerini C. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011 Oct 27;118(17):4567-76. Epub 2011 Aug 24. Erratum in: Blood. 2013 Oct 3;122(14):2524. [http://www.bloodjournal.org/content/118/17/4567.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916618/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21865346 PubMed]
## '''Update:''' Khoury HJ, Cortes JE, Kantarjian HM, Gambacorti-Passerini C, Baccarani M, Kim DW, Zaritskey A, Countouriotis A, Besson N, Leip E, Kelly V, Brümmendorf TH. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood. 2012 Apr 12;119(15):3403-12. Epub 2012 Feb 27. [http://www.bloodjournal.org/content/119/15/3403.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916559/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22371878 PubMed]
## '''Update:''' Kantarjian HM, Cortes JE, Kim DW, Khoury HJ, Brümmendorf TH, Porkka K, Martinelli G, Durrant S, Leip E, Kelly V, Turnbull K, Besson N, Gambacorti-Passerini C. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Blood. 2014 Feb 27;123(9):1309-18. Epub 2013 Dec 17. [http://www.bloodjournal.org/content/123/9/1309.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467890/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24345751 PubMed]
## '''Update:''' Gambacorti-Passerini C, Brümmendorf TH, Kim DW, Turkina AG, Masszi T, Assouline S, Durrant S, Kantarjian HM, Khoury HJ, Zaritskey A, Shen ZX, Jin J, Vellenga E, Pasquini R, Mathews V, Cervantes F, Besson N, Turnbull K, Leip E, Kelly V, Cortes JE. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up. Am J Hematol. 2014 Jul;89(7):732-42. Epub 2014 Apr 28. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4173127/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24711212 PubMed]
## '''Update:''' Gambacorti-Passerini C, Kantarjian HM, Kim DW, Khoury HJ, Turkina AG, Brümmendorf TH, Matczak E, Bardy-Bouxin N, Shapiro M, Turnbull K, Leip E, Cortes JE. Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors. Am J Hematol. 2015 Sep;90(9):755-68. Epub 2015 Jun 1. [https://onlinelibrary.wiley.com/doi/10.1002/ajh.24034/full link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5132035/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26040495 PubMed]

==Dasatinib monotherapy {{#subobject:da3870|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 70 mg twice per day {{#subobject:95626f|Variant=1}}=== 
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.bloodjournal.org/content/109/8/3207.long Cortes et al. 2006 (START-B/START-L)]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916944/ Kantarjian et al. 2009 (CA180-035)]
|style="background-color:#1a9851"|Phase III (C)
|Dasatinib 140 mg daily
|style="background-color:#ffffbf"|Seems not superior (*)
|-
|}
''Note: reported efficacy for CA180-035 is based on the 2010 subgroup analysis.''
====Chemotherapy====
[[Dasatinib (Sprycel)]] 70 mg PO twice per day

===Variant #2, 140 mg/day {{#subobject:8e78eb|Variant=1}}=== 
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916944/ Kantarjian et al. 2009 (CA180-035)]
|style="background-color:#1a9851"|Phase III (E)
|Dasatinib 70 mg twice per day
|style="background-color:#ffffbf"|Seems not superior (*)
|-
|}
''Note: reported efficacy for CA180-035 is based on the 2010 subgroup analysis.''
====Chemotherapy====
[[Dasatinib (Sprycel)]] 140 mg PO once per day

===References===
# '''START-B/START-L:''' Cortes J, Rousselot P, Kim DW, Ritchie E, Hamerschlak N, Coutre S, Hochhaus A, Guilhot F, Saglio G, Apperley J, Ottmann O, Shah N, Erben P, Branford S, Agarwal P, Gollerkeri A, Baccarani M. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood. 2007 Apr 15;109(8):3207-13. Epub 2006 Dec 21. [http://www.bloodjournal.org/content/109/8/3207.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17185463 PubMed]
# '''CA180-035:''' Kantarjian H, Cortes J, Kim DW, Dorlhiac-Llacer P, Pasquini R, DiPersio J, Müller MC, Radich JP, Khoury HJ, Khoroshko N, Bradley-Garelik MB, Zhu C, Tallman MS. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood. 2009 Jun 18;113(25):6322-9. Epub 2009 Apr 15. [http://www.bloodjournal.org/content/113/25/6322.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916944/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/19369231 PubMed]
## '''Subgroup analysis:''' Lilly MB, Ottmann OG, Shah NP, Larson RA, Reiffers JJ, Ehninger G, Müller MC, Charbonnier A, Bullorsky E, Dombret H, Brigid Bradley-Garelik M, Zhu C, Martinelli G. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: results from a phase 3 study. Am J Hematol. 2010 Mar;85(3):164-70. [https://onlinelibrary.wiley.com/doi/10.1002/ajh.21615/pdf link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20131302 PubMed]
## '''Subgroup analysis:''' Saglio G, Hochhaus A, Goh YT, Masszi T, Pasquini R, Maloisel F, Erben P, Cortes J, Paquette R, Bradley-Garelik MB, Zhu C, Dombret H. Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. Cancer. 2010 Aug 15;116(16):3852-61. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.25123/full link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993589/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20564086 PubMed]

==Imatinib monotherapy {{#subobject:a1dd0|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:a9797e|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM200104053441402 Druker et al. 2001]
|style="background-color:#ffffbe"|Phase I
|-
|[http://www.bloodjournal.org/content/99/10/3530.long Sawyers et al. 2002]
|style="background-color:#91cf61"|Phase II
|-
|}
''Note: these studies used doses ranging from 300 to 1000 mg PO once per day. This is the FDA-recommended dose.''
====Chemotherapy====
*[[Imatinib (Gleevec)]] 600 mg PO once per day

'''Continued indefinitely'''

===References===
# '''Phase I:''' Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001 Apr 5;344(14):1038-42. [https://www.nejm.org/doi/full/10.1056/NEJM200104053441402 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11287973 PubMed]
<!-- Presented in part at the 43rd Annual Meeting of The American Society of Hematology, Orlando, FL, December 11, 2001. -->
# Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, Schiffer CA, Talpaz M, Guilhot F, Deininger MW, Fischer T, O'Brien SG, Stone RM, Gambacorti-Passerini CB, Russell NH, Reiffers JJ, Shea TC, Chapuis B, Coutre S, Tura S, Morra E, Larson RA, Saven A, Peschel C, Gratwohl A, Mandelli F, Ben-Am M, Gathmann I, Capdeville R, Paquette RL, Druker BJ. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002 May 15;99(10):3530-9. [http://www.bloodjournal.org/content/99/10/3530.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11986204 PubMed]

==Vincristine & Prednisone {{#subobject:7d31e7|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:af8942|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM197804132981503 Marks et al. 1978]
|style="background-color:#91cf61"|Non-randomized
|-
|}
''Of historic interest.''
====Chemotherapy====
*[[Vincristine (Oncovin)]]
*[[Prednisone (Sterapred)]]
===References===
# Marks SM, Baltimore D, McCaffrey R. Terminal transferase as a predictor of initial responsiveness to vincristine and prednisone in blastic chronic myelogenous leukemia: a co-operative study. N Engl J Med. 1978 Apr 13;298(15):812-4. [https://www.nejm.org/doi/full/10.1056/NEJM197804132981503 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/273142 PubMed]

=Response Criteria=
*Tam CS, Kantarjian H, Garcia-Manero G, Borthakur G, O'Brien S, Ravandi F, Shan J, Cortes J. Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood. 2008 Aug 1;112(3):516-8. Epub 2008 May 20. [http://www.bloodjournal.org/content/112/3/516.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4082324/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/18492956 PubMed]
*[http://bloodref.com/myeloid/cml/cml-response CML response criteria (BloodRef.com)] based on 2013 European LeukemiaNet Recommendations for Management of Chronic Myeloid Leukemia

=Risk Scores=
*[http://bloodref.com/myeloid/cml/eutos EUTOS Score (BloodRef.com)]
*[http://bloodref.com/myeloid/cml/sokal-hasford Sokal & Hasford Relative Risk Scores (BloodRef.com)]

[[Category:Chronic myelogenous leukemia regimens]]
[[Category:Disease-specific pages]]
[[Category:Myeloproliferative neoplasms]]
